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 1 
1 INTRODUCTION 
 
 
Blood platelets play a crucial role in primary arterial hemostasis through 
adhesion to the vessel wall, subsequent aggregation and thrombus formation 
induced by collagen, von Willebrand factor, thrombin, and other factors exposed 
at sites of vascular injury. Under pathophysiological conditions, such as 
atherosclerosis, plug formation can cause inappropriate vascular occlusions 
resulting in myocardial infarctions or stroke, which represent major health risks 
today. Therefore, during the last decades increasing efforts have been made to 
elucidate the signalling mechanisms involved in platelet activation not least with 
the purpose to provide a basis for developing antiplatelet drugs and strategies. 
Platelet activation induced by primary agonists involves subsequent secretion of 
platelet-derived proaggregatory mediators, including the adenine nucleotides 
adenosine 5'-triphosphate (ATP) and adenosine 5'-diphosphate (ADP), as well 
as the generation and release of lipid mediators such as thromboxane A2 
(TXA2). 
Once released, these mediators generate stimulatory loops by activating their 
respective platelet receptors thereby representing important reinforcement 
mechanisms for platelet functions. 
TXA2 is the major arachidonic acid metabolite endogenously produced by 
platelets. Arachidonic acid is converted by cyclo-oxygenase generating the 
prostaglandin endoperoxide PGH2 which is sequentially transformed into TXA2 
by thromboxane synthase (Samuelsson et al. 1978). For TXA2, the 
thromboxane/prostanoid receptor α (TPα), a member of the G protein-coupled 
receptor (GPCR) family, is the predominant isoform expressed on platelets and 
couples to Gq as well as G12/13 proteins (Habib et al. 1999, Offermanns et al. 
1994). 
Platelet adenine nucleotide receptors can be distinguished as three separate 
subtypes of the purinergic type 2 (P2) receptor family, namely P2X1, P2Y1, and 
P2Y12. The P2Y12 receptor, that has just recently been cloned (Hollopeter et 
al. 2001, Zhang et al. 2001) was formerly variously designated as P2YADP, 
P2YAC, P2Ycyc, or P2TAC. 
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The P2X1 ATP receptor, that on platelets for long has been mistaken for an 
ADP receptor, is a ligand-gated ion channel, inducing a rapid calcium influx 
associated with transient shape change of human platelets (Mahaut-Smith et al. 
2000, Rolf et al. 2001). 
For ADP, two metabotropic GPCRs are presently known on platelets: P2Y1 and 
P2Y12 receptors. The signalling principles of these ADP receptor subtypes as 
well as their distinct contribution to platelet functions are fairly well understood; 
the number of affected molecules identified within these pathways is growing 
(for reviews see Gachet 2001, Kunapuli et al. 2003, Hechler et al. 2005). The 
P2Y1 ADP receptor couples to Gq, leading to a transient calcium mobilization 
from intracellular stores and initiating platelet shape change and aggregation. 
The P2Y12 ADP receptor couples to an inhibitory G protein, identified as Gi2 
(Ohlmann et al. 1995). Gi2 dissociation leads via β/γ-subunits to the activation of 
phosphoinositide 3-kinase (PI 3-K) which mediates the potentiation of dense 
granules secretion, and via αi-subunits to the inhibition of adenylyl cyclase that 
is essential for full and sustained platelet aggregation and thrombus formation. 
In addition, P2Y12 receptor-induced Gi2 signalling plays an important role in the 
activation of the fibrinogen receptor integrin αIIbβ3 (Kauffenstein et al. 2001, 
Jantzen et al. 2001, Nieswandt et al. 2002).  
The P2Y12 receptor is the target of the active metabolites of the thienopyridine 
drugs ticlopidine and clopidogrel which selectively and irreversibly inhibit its 
activation by ADP (for review see Savi et al. 2005). Besides competitively acting 
P2Y12 receptor antagonists such as the ATP-analogue AR-C69931MX (now 
designated cangrelor) these compounds potently inhibit platelet responses to all 
platelet agonists depending on their stimulatory intensities, emphasizing the 
crucial implication of P2Y12 receptor signalling in platelet activation and 
aggregation. In addition, these antagonists were indispensable to determine the 
specific roles of P2Y12 receptor signalling in platelet function (for reviews see 
Dorsam et al. 2004, Hechler et al. 2005). 
Studies with exogenously added ADP alone have pinpointed the mechanisms 
and roles for both the P2Y1 and P2Y12 receptors and revealed that in ADP-
induced platelet activation and aggregation the cooperation of both Gq-coupled 
P2Y1- and Gi-coupled P2Y12-receptor signalling is required (Hechler et al. 
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1998). In contrast, platelet activation and aggregation caused by strong 
agonists that directly activate Gq-coupled receptors, such as thrombin and 
TXA2, is dependent on subsequent P2Y12 receptor signalling rather than on 
P2Y1 receptor signalling (Nylander et al. 2003, Paul et al. 1999). The response 
to collagen, mediated mainly via glycoprotein VI (GP VI) that induces down-
stream protein tyrosine kinase cascades, strongly relies on intermediate TXA2 
signalling, subsequent ADP release, and P2Y12 receptor signalling (Nieswandt 
et al. 2001). Thus, Gi coupling in response to thrombin, collagen, and TXA2, is a 
subsequent event following ADP secretion and activation of P2Y12 ADP 
receptors (Kim et al. 2002, Paul et al. 1999, Nieswandt et al. 2001). 
 
Human platelets contain several members of the mitogen-activated protein 
kinase (MAPK) family, such as p38 MAP kinase (Kramer et al. 1995), c-Jun 
amino-terminal kinases (JNKs) (Bugaud et al. 1999), and the extracellular 
signal-regulated kinases 1 and 2 (ERK1 and ERK2) (Papkoff et al. 1994) as well 
as both ERK upstream kinases MEK1 and MEK2 (MAP/ERK kinases 1 and 2) 
(McNicol et al. 2001). 
Following platelet stimulation by primary agonists such as thrombin and 
collagen, all platelet MAPK family members become phosphorylated and 
therefore are presumably active. 
MAPKs represent a family of evolutionary conserved serine/threonine kinases 
that have been implicated during the last decades in a wide variety of 
mammalian cellular functions; ranging from gene expression, cell proliferation 
and differentiation, cell motility, to cell survival and death. Besides nuclear 
targets, MAPK activation affects substrates in the cell membrane, the cytosol, 
the cytoskeleton as well as mitochondria. 
The most eminent and best examined members of this family are ERK1 and 
ERK2, also designated p44 MAPK and p42 MAPK, respectively, as well as c-
Jun N-terminal kinases or stress-activated protein kinases (JNK/SAPK) and p38 
kinases. The diverse signalling pathways leading to MAPK activation as well as 
the various affected cellular substrates and functions have been substantially 
summarized and reviewed in detail (Chen Z. et al. 2001, Pearson et al. 2001, 
Roux et al. 2004). 
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ERK1 and ERK2 activation is initiated by extracellular stimuli via ligand-gated 
ion channels, receptor tyrosine kinases (RTKs), such as growth factor 
receptors, or by G protein-coupled receptors (GPCRs), all leading to the 
induction of various protein kinase cascades. These pathways finally funnel into 
the activation of the highly substrate-specific ERK upstream kinases MEK1 and 
2. In general, both MEK1 and 2 activate ERK1 and/or 2 by non-processive 
phosphorylation of tyrosine and threonine residues of a common Thr-Glu-Tyr 
(TEY) motif. 
ERK2, in particular, becomes first phosphorylated at Tyr-185, and after a 
threshold amount of this non-active form has accumulated, ERK2 is rapidly 
converted into its active form by additional phosphorylation at Thr-183. In ERK1, 
which shares over 80% sequence homology to ERK2, the signature motif is 
flanked by Thr-202 and Tyr-204. 
ERK activation induced by RTKs is mediated via the small GTP-binding protein 
Ras that activates Raf isoforms, such as Raf-1 and B-Raf. The increase in Raf 
activity is subsequently transduced through the MEK/ERK module. 
The mechanisms employed by GPCRs in ERK1/2 activation are multiple due to 
the various classes of G proteins as well as to the ability of some receptors to 
activate more than one species of G proteins (for reviews see Gudermann 
2001, Pierce et al. 2001, Luttrell et al. 2003). 
The activation of GPCRs, in general, causes the simultaneous activation and 
dissociation of G protein α- and β/γ-subunits. 
Gαq induces the activation of protein kinase C (PKC) isoforms, which in turn 
triggers the Ras/Raf kinase cascade resulting in the induction of MEK/ERK. 
The signalling cascades induced by Gs-coupled receptors are particularly 
diverse. The increase in cyclic AMP (cAMP) and activation of protein kinase A 
(PKA) was found to display cell type-specific inhibitory as well as excitatory 
features on ERK. From outstanding meaning were the findings by Robert J. 
Levkowitz and colleagues demonstrating that in HEK293 cells overexpressing 
β2-adrenoceptors the stimulation with isoproterenol induces a PKA-dependent 
switch of receptor coupling from Gαs to Gαi, and that ERK activation is finally 
mediated by the Gi pathway (Daaka et al. 1997) 
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ERK activation via Gi-coupled receptors is mediated by a β/γ subunit-dependent 
induction of phosphoinositide 3-kinase γ (PI-3Kγ) (Gutkind 1998). However, 
there is evidence that, besides PI-3Kγ, the non-receptor tyrosine kinase Src is 
implicated in the induction of the Ras/ERK signalling pathway downstream of Gi 
β/γ subunits (for review see Gudermann 2001). 
Furthermore, GPCRs provoke ERK activation by recruiting RTKs via ligand-
independent tyrosine-phosphorylation, a process that has become known as 
“transactivation”. Several GPCRs, such as the bradykin type 2 receptor and D4-
dopamin receptor, have been demonstrated to transactivate RTKs such as the 
epidermal-growth factor receptor (EGFR) and platelet-derived growth factor 
receptor β (PDGFRβ), respectively (Liebmann et al. 2000, Ferguson 2003). 
Daub et al. (1997) demonstrated in various cell types that both Gq- and Gi-
signals induce the transactivation of the EGFR. Following tyrosine 
phosphorylation of the EGFR, both GPCRs and EGFRs mediated ERK 
activation are indistinguishable as inhibiting the intrinsic EGFR tyrosine kinase 
activity blocks both EGFR and GPCR mediated ERK activation. 
Hence, G proteins appear able to access multiple protein kinase pathways to 
induce ERK activation. 
 
Although primary platelet agonists such as thrombin and collagen cause the 
activation of ERK2 (Papkoff et al. 1994, Nakashima et al. 1994, Börsch-Haubold 
et al. 1995), the signalling pathways involved are not fully elucidated. 
Thrombin-induced ERK2 activation in human platelets is dependent on MEK1/2 
activity (Börsch-Haubold et al. 1996, McNicol et al. 2003) and is mediated by 
protein kinase C (PKC) and calcium but not, in contrast to nucleated cells, by 
Raf-1 or B-Raf (Börsch-Haubold et al. 1995, Nadal-Wollbold et al. 2002). 
Moreover, whereas integrin signalling induces ERK2 activation in various cell 
types (for reviews see Giancotti et al. 1999, Juliano et al. 2004), during platelet 
aggregation fibrinogen binding-induced αIIbβ3 outside-in signalling inhibits 
platelet ERK2 activity (Nadal et al. 1997, Pawlowski et al. 2002). 
Thus, although ERK2 activity appears precisely regulated in platelets during 
activation and aggregation by consecutive signalling pathways, the regulatory 
principles apparently deviates from those in nucleated cells. 
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As mentioned above, platelet activation evokes the release of platelet-derived 
second mediators such as TXA2 and ADP. In concert with the primary stimulus 
these mediators support and enhance platelet activation via Gq-coupled TPα 
TXA2 receptors, as well as, and even more important, Gi-coupled P2Y12 ADP 
receptors, respectively. 
In a previous study using HEK293T cells as well as mouse and human 
fibroblasts it has been demonstrated that ERK2 activation by GPCRs relies on 
the cooperation of Gq and Gi signals (Blaukat et al. 2000). 
Therefore, within this work the question has been addressed whether this 
mechanism also applies for ERK2 activation in human platelets. In addition, the 
respective platelet-specific pathways involved as well as the functional 
implication of ERK2 in platelet activation and aggregation have been 
investigated. 
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2 AIM OF THE WORK 
 
 
The present work was set up to investigate the signalling pathways implicated in 
the activation and regulation of the extracellular signal-regulated kinase 2 
(ERK2) in human platelets. 
Isolated platelets were used to exclude interactions with other blood cells as 
well as effects of plasma components. 
Platelet activation and aggregation induced by primary platelet agonists such as 
thrombin or collagen are accompanied by the release and autocrine actions of 
secondary, platelet-derived mediators such as TXA2 and ADP. 
To answer the question if or how these mediators contribute to ERK2 activation 
several receptor-specific antagonists as well as enzyme inhibitors affecting 
important signalling pathways should be applied. 
ERK2 activity should be assessed by immuno(Western)blotting using activation-
specific antibodies. 
Finally, the controversially discussed issue whether ERK2 is involved in primary 
platelet responses such as granule release, integrin αIIbβ3 activation, and 
platelet aggregation should be addressed. As isolated platelets were used, 
appropriate experimental methods and protocols were about to be modified 
and/or adapted such as secretion assays and fluorescence-activated cell-
sorting (FACS) analysis. 
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3 ABBREVIATIONS 
 
 
[3H]5-HT [3H]5-hydroxytryptamine 
2-MeS-ADP 2-(methylthio)adenosine 5'-diphosphate 
5-HT 5-hydroxytryptamine 
A3P5P adenosine 3'5'-diphosphate 
ADP adenosine 5'-diphosphate 
APS ammonium persulfate 
ATP adenosine 5'-triphosphate 
BSA bovine serum albumine 
cAMP cyclic adenosine mono-phosphate 
CD61 cluster of differentiation 61 (integrin αIIbβ3) 
CD62 cluster of differentiation 62 (P-selectin) 
ddH2O double-distilled H2O 
DMSO dimethylsulfoxid 
ECL enhanced chemoluminescence 
EGF(R) epidermal-growth factor (receptor) 
ERK(s) extracellular signal-regulated kinase(s) 
FACS fluorenscence-activated cell sorting 
FITC fluorescin isothiocyanate 
GP VI glycoprotein VI 
GPCR(s) G protein-coupled receptor(s) 
Hepes N-2-hydroxyethylpiperazin-N'-2-ethyan-sulfonic acid 
MAPK(s) mitogen-activated protein kinase(s) 
MEK MAP/ERK kinase 
NC(s) nitrocellulose membrane(s) 
PBS phosphate-buffered saline 
PDGF(R) platelet-derived growth factor (receptor) 
PE phycoerythrin 
PerCP peridinin chlorophyll protein 
PI 3-K phosphoinositide 3-kinase 
PKA protein kinase A 
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PKB protein kinase B 
PKC protein kinase C 
RGDS Arg-Gly-Asp-Ser (-peptide) 
RTK(s) receptor tyrosine kinase(s) 
SDS sodium dodecylsulfate 
TEMED N, N, N', N'-tetramethylethylenediamine 
TP thromboxane / prostanoid receptor  
Tris tris-(hydroxymethyl)-aminomethan 
TXA2 thromboxane A2 
U unit(s) 
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4 MATERIALS AND METHODS 
 
 
4.1 Materials 
 
4.1.1 Chemicals 
Substance           Source 
β-Mercaptoethanol Sigma 
2-Propanol Roth 
Acetic acid Merck 
Acrylamid (rotiphorese Gel 30) Roth 
APS (ammonium persulfate) Merck 
BSA (bovine serum albumine, grade V) Sigma 
CaCl2 Merck 
Citric acid AppliChem 
Coomassie-R250 (brilliant blue R250) Roth 
DMSO (dimethylsulfoxid) Sigma 
ECL (Enhanced Chemiluminiscence (ECL) 
 Western Blotting Detection System) 
Amersham 
Biosciences 
Ethanol Merck 
Formic acid Merck 
Glucose (α-(+)D-glucose) Merck 
Glutaraldehyde Sigma 
Glycerol Serva 
Glycine Serva 
HCl, fuming, 37% Merck 
Hepes (N-2-hydroxyethylpiperazin-N'-2-ethyan- 
  sulfonic acid) 
Roth 
KCl Merck 
Methanol Merck 
MgCl2 Merck 
Na2HPO4 Merck 
NaCl  Merck 
NaH2PO4 Merck 
NaN3 Merck 
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NaOH Merck 
Nonfat dry milk Roth 
PBS, (phosphate-buffered saline) without Ca2+, Mg2+ Biochrom AG 
Ponceau-S (3-hydroxy-4-[2-sulfo-4-(4-sulfo-phenylazo) 
 phenylazo]-2,7-naphthalenedisulfonic acid) 
Sigma 
SDS (sodium dodecylsulfate) Serva 
Sodium citrate Merck 
TEMED (N, N, N', N'-tetramethylethylenediamine) Sigma 
Tris (tris-(hydroxymethyl)-aminomethan) Roth 
Tween-20 (polyoxyethylenesorbitan monolaurate) Sigma 
Urea Roth 
 
4.1.2 Radiochemicals 
[5-[α,β-3H(N)]-hydroxtryptamine creatinine sulfat 
(2 Ci/mmol; 1 Ci/ml) 
PerkinElmer Life 
Sciences 
 
4.1.3 Agonists 
2-MeS-ADP (2-(methylthio)adenosine 5'-diphosphate) Sigma 
ADP (adenosine 5'-diphosphate) Sigma 
Collagen Nycomed 
Epinephrine Sigma 
Thrombin, from bovine origin Sigma 
U46619 ([9,11-dideoxy-11α, 9 α-epoxy-methanoprosta- 
  glandine (F2α)]) 
Sigma 
 
4.1.4 Antagonists and Inhibitors 
A3P5P (adenosine 3'5'-diphosphate) Sigma 
Apyrase, grade III, from potato Sigma 
AR-C69931MX (N6-methylthioethyl-, 2-trifluoropropyl- 
                          thio-D-β-γ-dichloromethylene-ATP) 
kindly provided 
by AstraZeneca, 
Wilmington, DE, 
USA 
Aspirin (acetylsalicylic acid) Sigma 
Fluoxetine (N-methyl-3-[(4-trifluoromethyl)-phenoxy]-3- 
                   phenylpropylamine hydrochloride) 
Tocris 
Hirudin, recombinant Pentapharm 
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LY294002 (2-(4-morhpholinyl)-8-phenyl-4H-1-benzopyran- 
                   4-one) 
Biomol 
MRS2179 (N6-methyl, 2'-deoxyadenosine 3', 5'-biphoshate) Tocris 
PD98059 (2-(2-amino-3-methoxyphenyl) oxanaphtalen- 
                  4-one) 
Biomol 
RGDS (Arg-Gly-Asp-Ser-peptide) Sigma 
S1197 (3-{2-[4-(S)-(4-aminoimino-methyl-phenyl)-4-methyl- 
             2,5-dioxo-imidazolidin-1-yl]acetyl-amino}-3-(S)- 
             phenylpropionic acid hydro-chloride) 
kindly provided 
by Aventis 
Pharma, 
Frankfurt a.M. 
SQ22536 (9-(tetrahydro-2'-furyl)adenite) Calbiochem 
SQ29548 [1S-[1α, 2α(Z), 3α, 4α]]-7-[[2- [(phenylamino)  
                 carbonyl]hydrazino] methyl]-7-oxabicyclo  
                 (2.2.1)hept-2-yl]-5-heptenoic acid 
Biomol 
U0126 (1,4-diamino-2,3-dicyano-1,4-bis 
             [2-aminophenylthio] butadiene) 
Cell Signaling 
Technology, Inc. 
Wortmannin Sigma 
 
For all applications double-distilled water (ddH2O) was used. 
 
4.1.5 Antibodies 
Primary antibodies  
Anti-pT183 MAPK, rabbit polyclonal antibody; recognizing 
ERK1 and 2 when mono-phosphorylated at Thr-residues 
Promega 
ERK 1 (K-23), rabbit polyclonal antibody; recognizing 
unmodified ERK 1 and 2  
Santa Cruz Bio 
technology, Inc. 
ERK 2 (D2), mouse monoclonal antibody; recognizing 
unmodified ERK 2  
Santa Cruz Bio 
technology, Inc. 
p-ERK (E4), mouse monoclonal antibody; recognizing 
ERK1 and 2 when mono-phosphorylated at Tyr-residues 
Santa Cruz Bio-
technology, Inc. 
Phospho-Akt (Ser473) (587F11), mouse monoclonal 
antibody 
Cell Signaling 
Technology, Inc. 
Phospho-p44/p42 MAPK (E10), mouse monoclonal 
antibody; recognizing ERK 1 and 2 only when dually-
phosphorylated at Tyr- and Thr-residues 
Cell Signaling 
Technology, Inc.  
 
Secondary antibodies  
Polyclonal swine anti-rabbit IgG, 
horseradish peroxidase (HRP)-conjugated 
DakoCytomation 
GmbH 
Polyclonal rabbit anti-mouse IgG, 
horseradish peroxidase (HRP)-conjugated 
DakoCytomation 
GmbH 
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4.1.6 Antibodies for flow cytometry 
Antibody   
CD61 (anti-integrin β3), peridinin chlorophyll protein 
(PerCP)-conjugated 
BD Biosciences 
CD62P, phycoerythrin (PE)-conjugated BD Biosciences  
Mouse IgG1 Platelet Control; phycoerythrin (PE)-conjugated BD Biosciences 
PAC-1, fluorescin isothiocyanate (FITC)-conjugated BD Biosciences 
 
 
4.2 Methods 
 
4.2.1 Preparation of washed human platelets 
Suspensions of washed human platelets were prepared as previously described 
(Martinson et al. 1995). After received informed consent according to the 
permission of the Ethic Board of the Martin-Luther-University Halle-Wittenberg, 
60-80 ml blood was drawn from healthy volunteers (who denied to have taken 
any medication 2 weeks prior to donation) from the antecubital vein using  
21 gauge winged infusion sets (Becton Dickinson, Helsingborg, Sweden) and 
20 ml single-use syringes (B. Braun, Melsungen, Germany). Blood was 
transferred in a volumetric proportion of 6:1 to acid-citrate-dextrose formula A 
(ACD-A: 38 mM citric acid, 88 mM sodium citrate, 124 mM glucose) into 13 ml 
centrifugation tubes (95x16.8mm in diameter, Sarstedt, Nümbrecht, Germany), 
and centrifuged at 120 x g for 15 min. To the platelet-rich plasma thus obtained 
were added (per ml) 111 µl ACD-A and 1 U apyrase (1 U/µl solution), and 
platelets were collected by centrifugation at 450 x g for 7 min. The platelet pellet 
was resuspended in modified Tyrode’s buffer (137 mM NaCl, 2.7 mM KCl, 
10 mM Hepes, 0.36 mM NaH2PO4, 1 mg/ml glucose; pH 6.4) supplemented with 
1 U/ml apyrase and 1 U/ml hirudin, incubated at 37°C for 15 min, and 
centrifuged at 450 x g for 7 min. The washing step was repeated once using the 
modified Tyrode's buffer without hirudin, and platelets were finally suspended in 
the same buffer adjusted to pH 7.4 and supplemented with 2 mM CaCl2, 2 mM 
MgCl2, and 0.02 U/ml apyrase, designated as suspension buffer. After 
determining the platelet count using a Neubauer chamber, suspensions were 
adjusted to platelet concentrations required for different experimental 
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procedures. All preparation steps were carried out at room temperature if not 
otherwise indicated. For centrifugation a Hermle Z364 centrifuge with an out-
swing bucket rotor was used (Hermle, Wehingen, Germany). 
Hirudin was applied in the first washing step to irreversible complex and 
inactivate residual traces of thrombin. The nucleotidase apyrase (EC 3.6.1.5), 
scavenging ATP and ADP, was present throughout all preparation steps. 
Platelet suspensions were finally allowed to rest for 30 min at 37°C prior to 
experimental procedure for recovering P2Y1 receptors (Baurand et al. 2000, 
Cazenave et al. 2004). 
All experimentally applied compounds were diluted with suspension buffer. For 
substances insoluble in water, respective solvent controls were carried out and 
effects, if any, are mentioned in the Results section. 
 
4.2.2 Platelet aggregation 
Prepared platelets were diluted to 3x108 platelets/ml in suspension buffer. 
Experiments were carried out at 37°C in a platelet aggregation profiler (PAP4 
Bio/Data Corp., Hatboro, PA, USA) using siliconized test tubes and magnetic 
stirrers rotating at 900 r.p.m. according to the method of Born (1962). The 
principle of this method is monitoring light transmission through a stirred platelet 
suspension. As shown in the schematic presentation given below, after addition 
of an agonist such as thrombin the light transmission transiently decreases as 
platelets undergo a morphological "shape change" from their initial discoid to a 
spherical form with developing filopodia. During the course of platelet 
aggregation the light transmission increases due to full platelet aggregation and 
growing size of aggregates. 
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Schematic presentation of platelet morphological changes during aggregation
and visualization by monitoring light transmission in an aggregometer
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Aggregation is expressed as percentage light transmission compared to 
suspension buffer alone (=100%). Preincubations with antagonists were carried 
out in the siliconized test tubes as indicated in the respective figure legend in an 
Eppendorf thermomixer rotating at 700 r.p.m. at 37°C. Platelet aggregation 
profiles induced by various concentrations of thrombin or respective agonists 
served as internal controls to asses the quality of each platelet preparation.  
 
 
4.2.3 Platelet stimulation, detection and quantification of 
phosphorylated proteins 
 
4.2.3.1 Platelet stimulation 
For experiments performed to determine protein phosphorylation washed 
platelets were adjusted to 5x108 platelets/ml with suspension buffer. Incubations 
were carried out at 37°C in a total volume of 200 µl in a 2 ml round-bottom tube 
containing a stainless steel sphere (2 mm diameter; SKF, Schweinfurt, 
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Germany) in an Eppendorf thermomixer rotating at 700 r.p.m. Except for aspirin, 
that was present while platelets were allowed to rest for 30 min prior to 
experimental procedures with occasional gently agitation, preincubations with 
antagonists or buffer were carried out as indicated in the figure legends at 37°C 
with stirring at 700 r.p.m. Reactions were stopped by the addition of 50 µl SDS-
sample buffer (10% SDS, 1.43 M β-mercaptoethanol, 20% glycerol, 26% urea, 
125 mM Tris-HCl, pH 6.8 (all w/v solutions)), and proteins were denaturated at 
95°C for 5 min. From these samples 25 µl were used for SDS-PAGE (equal 
total amount of protein from 1x107 platelets). 
 
4.2.3.2 SDS- Polyacrylamid Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE was performed according to the method described by Laemmli 
(Laemmli 1970). Proteins were separated at room temperature by 10% SDS-
PAGE using BioRad Protean II minigel system (BioRad, München, Germany) 
applying a current of 20 mA per gel. Resolving gels consist of 33.3 % (v/v) 
acrylamid, 50 % (v/v) Tris-HCl (0.75 M, pH 8.8), 0.5 % (v/v) SDS (20 % solution 
(w/v)), 0.05 % (v/v) TEMED, 15.45 % (v/v) ddH2O and 0.7 % (v/v) APS (10 % 
solution (w/v)) and stacking gels of 16,7 % (v/v) Acrylamid, 12,5 % (v/v) Tris-
HCl (0,625 M, pH 6,8), 0,5 % (v/v) SDS (20 % solution (w/v)), 0,1 % (v/v) 
TEMED, 69,7 % (v/v) ddH2O und 0,5 % (v/v) APS (10 % solution (w/v)). As 
running-buffer 25 mM Tris, 200 mM glycine, and 1% (w/v) SDS adjusted to pH 
8.3 was used.  
To determine apparent molecular protein masses according to Weber and 
Osborn (1969) the following marker proteins (in SDS-sample buffer) were used: 
BSA (66 kDa), catalase (60 kDa), ovalbumin (45 kDa), glycerinaldehyd-3-
phosphatdehydrogenase (36 kDa), carbonic anhydrase (29 kDa); all purchased 
from Sigma. 
 
4.2.3.3 Immuno(Western)blotting and detection of phosphorylated 
proteins 
Following SDS-PAGE gels were subjected to immuno(Western)blotting using 
BioRad Mini Trans-Blot cells (BioRad, München, Germany) and proteins were 
transferred onto nitrocellulose membranes (NCs) (Protran BA85, 
Schleicher&Schuell, Dassel, Germany) at 4°C for 2.5 hrs applying a current of 
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2.5 mA per mm2 NC. Transfer buffer consisted of 192 mM Glycin, 27 mM Tris, 
20 % (v/v) Methanol, 0.015 % (w/v) SDS; pH 8.3-8.4 ,not adjusted. 
To ensure proper blotting efficiency gels were dyed for fixing residual proteins 
with Coomassie brilliant blue (25% (v/v) 2-propanol, 10% (v/v) acetic acid, 
0.05% (w/v) Coomassie-R250) for 10 min and gels were rinsed with 10% acetic 
acid. Proteins transferred to NCs were reversibly dyed with Ponceau-S red, 
bands of reference proteins were marked with a soft pencil and NCs were 
subsequently undyed with TBS-T (10 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.1% 
(w/v) Tween-20). TBS-T was used for all further blocking and washing 
procedures, as well as antibody dilutions. NCs were gently agitated throughout 
all steps of analysis. Surplus protein binding sites were saturated to avoid 
unspecific antibody binding by blocking NCs as indicated with either 5% (w/v) 
BSA, 5% (w/v) nonfat dry milk, or both, for 2 hours at room temperature. 
NCs were incubated with primary antibodies at 4 °C over night. After washing  
(3 times for 10 min at room temperature), secondary antibodies were applied for 
2 hrs at room temperature. Dependent on the applied primary antibody, the 
different blocking substances, primary, and respective secondary antibody 
dilutions are listed in the following table: 
Primary antibody Blocking 
solution 
Primary anti-
body dilution 
Secondary 
antibody / dilution 
Phospho-p44/p42 
MAPK (E10) 
5% nonfat dry 
milk 
1:500 in 5% 
nonfat dry milk* 
anti-mouse IgG 
1:1000 
p-ERK (E4) 5% BSA / 5% 
nonfat dry milk 
1 µg/ml in 5% 
BSA 
anti-mouse IgG 
1:1000 
Anti-pT183 MAPK 5% BSA 1:1000 in 5% 
BSA* 
anti-rabbit IgG 
1:1000 
ERK 1 (K-23) 5% BSA / 5% 
nonfat dry milk 
1:500 in 5% BSA 
 
anti-rabbit IgG 
1:2000 
ERK 2 (D2) 5% nonfat dry 
milk 
0.4 µg/ml in 5% 
BSA 
anti-mouse IgG 
1:1000 
Phospho-Akt 
(Ser473) (587F11) 
5% nonfat dry 
milk 
1:1000 in 5% 
nonfat dry milk* 
anti-mouse IgG 
1:1000 
* concentration cannot be given due to missing details in available product datasheets 
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After washing of uncoupled secondary antibodies (3 times for 10 min at room 
temperature), the bands of interest were visualized by the use of the „Enhanced 
Chemiluminiscence (ECL) Western Blotting Detection System“ (Amersham 
Biosciences) according to the manufacturer's protocol. The principle of this 
method is that luminol is formed in the presence of H2O2 by peroxidase coupled 
to the secondary antibody. Resulting chemiluminiscence (light emission) was 
detected by exposure of NCs to X-ray films (Hyperfilm, Amersham 
Biosciences). Exposure times varied between 2 and 60 sec. 
For re-probing NCs, primary and secondary antibodies were stripped off by 
incubation in TBS containing 0.05% (w/v) Tween-20, 2% (w/v) SDS, and 1% 
(v/v) β-mercaptoethanol for 30 min at 70°C followed by re-equilibrating NCs with 
TBS-T (3 times for 30 min at room temperature).  
 
4.2.3.4 Visualizing and quantification of phosphorylated protein 
Emerging X-ray films were scanned with a GS800 densitometer (BioRad, 
München, Germany). Phosphorylation intensities were evaluated by quantitative 
densitometry using Quantity One software version 4.2.1 (BioRad, München, 
Germany) within a determined linear density range from 0 to 160 optical 
densities (OD) per mm2 area. Graphics were processed with Adobe Photoshop 
5.0 software (Adobe Systems Inc., San Jose, CA, USA). 
 
 
4.2.4 Determination of platelet dense granule release by 
[3H]5-hydroxytryptamine release assay 
Platelet suspensions were adjusted to 1x109 platelets/ml and labeled with  
1.5 µCi/ml [3H]5-hydroxytryptamine ([3H]5-HT; of a 0.1 µCi/µl dilution) in a 
waterbath at 37°C for 60 min with gentle agitation. Suspensions were 
centrifuged for 10 min at 700 x g (Hermle Z364). Radioactive supernatants were 
removed and pellets were resuspended in an estimated volume of suspension 
buffer yielding to approximately 5x108 platelets/ml. Fluoxetine (100 µM) was 
added 5 min prior to experiments to inhibit [3H]5-HT re-uptake during 
stimulation. Pretreatments and incubations were carried out as aforementioned 
(chapter 4.2.3.1). Reactions were stopped by the addition of 200 µl ice-cold 6% 
(v/v) glutaraldehyd (in NaH2PO4/Na2HPO4 buffer, pH 7.3). Samples were 
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centrifuged for 10 min at room temperature in an Eppendorf 5413 centrifuge (at 
fixed 11.500 r.p.m.). Without disrupting the platelet pellets, supernatants were 
completely transferred to 6 ml vials (PonyVials, Packard BioScience, (Canberra 
Packard, Dreieich, Germany)). Pellets were dried for 60 min at room 
temperature, and digested in 200 µl 80% formic acid at 37°C with occasional 
vortexing, and debris was also transferred to 6 ml vials. Tubes were rinsed once 
with 200 µl 80% formic acid (giving total volumes of 400 µl). To all vials 4 ml 
scintillation-cocktail (Lumasafe Plus, Lumac LSC, Groningen, The Netherlands) 
were added. After vigorously mixing, samples were equilibrated for 3 hrs before 
monitoring in a liquid scintillation analyzer (Packard, Canberra Packard, 
Dreieich, Germany). Radioactive decay was assessed by counting light 
emission for 10 min and was given as drops per min (dpm). [3H]5-HT secretion 
was calculated using the following equitation: 
 
edincorporat total of % in secretion
(contr.) supernat. dpm(contr.) pellet dpm
(contr.)] supernat. dpm(stim.) supernat. 100x[dpm =−
−
 
(supernat. = supernatant; contr. = control; stim. = stimulated) 
 
Radioactive waste was properly discarded. 
 
4.2.5 Determination of platelet α-granule secretion and integrin αIIbβ3 
activation by flow cytometric analysis 
For flow cytometric analysis platelet suspensions were diluted to 1x106 
platelets/ml. Treatments were carried out at room temperature with gentle 
agitation in a total volume of 200 µl in a 2 ml round-bottom tube. Pretreatments 
and incubation times are indicated in the respective figure legends. Reactions 
were stopped by transferring and therefore diluting 5 µl of the incubated 
suspensions into 12x75 mm tubes (Falcon, BD Biosciences, Heidelberg, 
Germany) containing 20 µl PerCP-conjugated CD61 antibody (3 µg/ml solution), 
20 µl PE-conjugated CD62P antibody (1.5 µg/ml solution), and 20 µl FITC-
conjugated PAC-1 antibody (25 µg/ml) (total volume 65 µl). For control, to 
detect and exclude nonantigen-specific binding sites, one sample contain 20 µl 
PE-conjugated Mouse IgG1 (25 µg/ml), 20 µl PerCP-conjugated CD61 antibody 
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(3 µg/ml solution), 20 µl FITC-conjugated PAC-1 antibody (25 µg/ml), and 10 µl 
RGDS (10 mg/ml solution) (total volume 75 µl).  
Samples were stained for 20 min at room temperature in the dark. After the 
addition of 1 ml PBS/0.1% sodium azide (room temperature) samples were 
stored at 4°C until analyzing within a time period of 5 to 15 min. 
Three-colour analysis of platelet activation was monitored by fluorescence-
activated cell-sorting (FACS) using a FACScalibur (Becton Dickinson, 
Heidelberg, Germany) with a laser excitation of 488 nm and specific bandpath 
filters for 530 nm (FITC), 585 nm (PE) and >650 nm (PerCP). 
The advantage of a three-colour analysis is the use of one fluorescent color, in 
this case PerCP conjugated with a CD61 antibody, to delimit data acquisition for 
analyzing exclusively platelets. The activation-independent but platelet-specific 
CD61 (integrin β3) antibody serves by its light-scatter profile to separate the 
platelet population from other cells, platelet-derived microparticels, or cell 
debris. The two other fluorescent colors, in this case PE and FITC, conjugated 
with CD62P and PAC-1 antibodies, respectively, were used to simultaneously 
asses the binding of platelet activation-dependent antibodies. Before each 
acquisition the platelet population was defined in a sample of unstimulated 
platelets according to cellular size and shape by forward scatter (FSC) versus 
side scatter (SSC) (Fig. A), and validated by fluorescence gating on CD61 
positive events (R1), allowing to precisely adjust the >650 nm filter (indicated 
with the arrow) (Fig. B). 
FSC-Height
SS
C
-H
ei
gh
t
100 101 102 103 10
100
101
102
103
104
platelet
population
A
4
SS
C
-H
ei
gh
t
CD61 PerCP
R1
B
100 101 102 103 104
100
101
102
103
104
 
 21 
The changes of platelets shape from “discocytes” to “spherocytes” upon 
stimulation with thrombin (0.1 U/ml) for 2 min within the scatter and 
fluorescence gating profile (R1) are demonstrated in Figs. C and D. 
100 101 102 103 104
100
101
102
103
104
100 101 102 103 104
100
101
102
103
104
FSC-Height
SS
C
-H
ei
gh
t
SS
C
-H
ei
gh
t
CD61 PerCP
C D
 
Within 10.000 events positively gated on CD61 (R1), unstimulated platelets 
were fluorescent gated on PAC-1 FITC versus CD62P PE positive events to 
trigger 530 nm (FITC) and 585 nm (PE) filters. Using a sample of unstimulated 
platelets, the CD61 positive gated platelet population was enclosed to an area 
>95% negative for binding of Mouse IgG1 and PAC-1 in the presence of RGDS, 
respectively (Fig. E). 
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In this setting, stimulated platelets (2 min with 0.1 U/ml thrombin) were acquired 
(Fig. F) and the CD61 positive platelet population was sorted on CD62P and/or 
PAC-1 positive events. 
Data were automatically analyzed by Cell Quest software (Becton Dickinson 
Immunocytometry Systems, San Diego, CA, USA) and CD62P and/or PAC-1 
positive assessed platelets were given in % of CD61 positive gated platelets. 
 
 
4.2.6 Statistical analysis 
Emerging data were processed with GraphPad Prism version 3.02 for Windows, 
GraphPad Software, San Diego, California, USA. Data is presented as 
mean±standard error mean (S.E.M.) and statistical analysis (p values) were 
determined by paired Student’s t tests. 
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5 RESULTS 
 
 
5.1 ERK2 activation induced by primary platelet agonists 
 
5.1.1 ERK2 activation in response to thrombin 
 
5.1.1.1 Time course of ERK2 phosphorylation and activation  
As mentioned in the Introduction section, ERK2 becomes phosphorylated by 
MEK1/2 first on Tyr-185 residues and in a second, non-processive step on 
Thr-183 residues, thereby converting ERK2 into its dual-phosphorylated active 
state. 
 
Fig. 1   Time course of platelet ERK2 phosphorylation in response to thrombin 
 
ERK2-YPTP 
ERK2-TP 
ERK2-YP 
ERK2 
Time (min)
[Thr] (0.1 U/ml)  ++++_ + + + +
0.5 0.5 1 2 3 4 6 8 10
Washed human platelets were challenged with 0.1 U/ml thrombin (Thr) or buffer for control for 
the indicated times at 37°C with stirring. Reactions were stopped by the addition of SDS-
sample buffer. Samples were analyzed by SDS-PAGE followed by immuno(Western)blotting
with sequential re-probing as described in “Materials and methods” using antibodies
recognizing ERK1 and 2, phosphorylated at Tyr-185 (-YP), Thr-183 (-TP), Tyr-185/Thr183
(-YPTP), or unmodified ERK2. Shown result is from one experiment that is representative of
4 similar experiments.
10
_
 
 
As shown in Fig. 1, ERK2 phosphorylation is not detectable in unstimulated 
platelets. Upon stimulation with 0.1 U/ml thrombin initial phosphorylation of 
ERK2 at Tyr-185 residues is observable within 30 sec. The state of maximal 
Tyr-185 phosphorylation peaks between 2 to 3 min and decreases afterwards 
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(upper chart). Phosphorylation of ERK2 at Thr-183 is detectable about 1 min 
after the onset of stimulation, peaks likewise within 2 to 3 min and diminishes 
subsequently (upper middle chart). The use of an antibody recognizing ERK2 
dual-phosphorylated at Tyr-185/Thr-183 reveals an identical time course (lower 
middle chart). Equal protein loading amounts were ensured by re-probing 
respective immuno(Western)blots using an antibody recognizing unmodified 
ERK2 (lower chart). 
As the dual-phosphorylated state of ERK2 resembles its active state it is 
therefore further referred to as activated ERK2. 
 
The time courses of ERK2 mono-phosphorylation at Tyr-185 and dual-
phosphorylated at Tyr-185/Thr183 were confirmed by quantitative densitometric 
analysis (Fig. 2). 
 
Fig. 2   Quantification of the time-dependent changes in the pattern of ERK2 
  phosphorylation upon thrombin-stimulation 
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X-ray films from the immuno(Western)blots, of which one is presented in Fig. 1, were 
densitometrically analyzed as described in “Materials and methods”. Data were processed by 
setting the maximal optical intensity of the respective band as 100% and are means±S.E.M. 
Error bars are not shown for data points having error that is smaller than the symbol. Shown 
graphs of ERK2 phosphorylated at Tyr-185 (-YP) and Tyr-185/Thr-183 (-YPTP) are from
4 experiments.
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5.1.1.2 ERK2 activation evoked by increasing concentrations of 
thrombin 
As shown in Fig. 3, incubating platelets with thrombin at a concentration of 0.05 
U/ml does not cause detectable ERK2 activation. Thrombin at 0.1 U/ml, more 
potently at 0.3 U/ml and most effectively at 1 U/ml induces the activation of 
ERK2. Higher concentrations of thrombin (up to 10 U/ml) do no further enhance 
ERK2 activation (data not shown). 
 
Fig. 3   ERK2 activation induced by increasing concentrations of thrombin 
 
ERK2-YPTP
ERK2 
[Thrombin] (U/ml)0.05_ 0.1 0.3 1
Washed human platelets were stimulated with the indicated concentrations of thrombin
for 2 min at 37°C with stirring. Reactions were stopped by the addition of SDS-sample buffer. 
Samples were analyzed by SDS-PAGE followed by immuno(Western)blotting with sequential
re-probing as described in “Materials and methods” using antibodies recognizing ERK1 and 2,
dually phosphorylated at Tyr-185/Thr-183 (-YPTP), or unmodified ERK2. Shown result is from 
one experiment that is representative of 3 similar experiments.
 
 
5.1.1.3 Effect of the ATP/ADP scavenger apyrase on ERK2 activation  
Apyrase is commonly used during platelet preparations to protect platelets from 
activation and aggregation induced by released ADP (compare "Materials and 
methods" chapter 4.2.1). Likewise, apyrase is a useful tool to investigate an 
overall involvement of released adenine nucleotides in agonist-induced platelet 
activation. Therefore, platelets were stimulated with thrombin in the presence of 
increasing concentrations of apyrase. As demonstrated in Fig. 4, ERK2 
activation induced by 0.1 U/ml thrombin is diminished by 1 and 10 U/ml and 
almost completely abolished by 50 U/ml apyrase. 
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Fig. 4   Effect of apyrase on thrombin-induced ERK2 activation 
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Washed human platelets were preincubated for 5 min at 37°C with buffer or apyrase at the 
indicated concentrations and stimulated with thrombin for 2 min at 37°C with stirring. Reactions 
were stopped by the addition of SDS-sample buffer. Samples were analyzed by SDS-PAGE 
followed by immuno(Western)blotting with sequential re-probing as described in “Material and 
methods” using antibodies recognizing ERK1 and 2, dually phosphorylated at Tyr-185/Thr-183
(-YPTP), or unmodified ERK1 and 2. Shown result is from one experiment that is representative 
of 3 similar experiments.
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5.1.1.4 Effects of specific P2Y receptor antagonists on ERK2 activation 
To discriminate between the ADP-receptor subtypes involved in thrombin-
induced ERK2 activation, platelets were stimulated in the presence of specific 
P2Y receptor antagonists (Fig 5). 
 
Fig. 5   Effects of specific P2Y receptor antagonists on ERK2 activation caused  
by thrombin 
Pretreatment
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Washed human platelets were preincubated with buffer, 10 µM AR-C69931MX (AR-C),
500 µM A3P5P, or 100 µM MRS2179 (MRS) for 5 min at 37°C with stirring and challenged with 
0.1 U/ml thrombin for 2 min. Reactions were stopped by the addition of SDS-sample buffer. 
Samples were analyzed by SDS-PAGE followed by immuno(Western)blotting with sequential 
re-probing as described in “Materials and methods” using antibodies recognizing ERK1 and 2, 
dually phosphorylated at Tyr-185/Thr-183 (-YPTP), or unmodified ERK2. Shown result is from 
one experiment that is representative of 5 similar experiments.  
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As demonstrated in Fig. 5, pretreatment with the highly specific, competitively 
acting P2Y12 receptor antagonist AR-C69931MX (10 µM) completely abrogates 
ERK2 activation caused by 0.1 U/ml thrombin, whereas the P2Y1 receptor 
antagonists A3P5P (500 µM) and MRS2179 (100 µM) have no effect. 
 
 
5.1.1.5 Effect of the P2Y12 receptor antagonist AR-C69931MX on ERK2 
activation in response to increasing concentrations of thrombin 
As demonstrated before, a concentration of 0.05 U/ml thrombin is not sufficient 
to evoke ERK2 activation (Fig. 3). ERK2 activation induced by 0.1 U/ml 
thrombin is completely abolished by pretreatment with 10 µM AR-C69931MX 
(Fig. 5) and, as shown in Fig. 6, the response to 0.3 U/ml thrombin is still 
markedly attenuated by 10 µM AR-C69931MX. ERK2 activation provoked by 
0.3 U/ml thrombin, however, cannot completely be prevented even when 
AR-C69931MX is applied up to 100 µM (data not shown). 
 
Fig. 6   Effect of AR-C69931MX on ERK2 activation induced by increasing 
               concentrations of thrombin 
 
Washed human platelets were preincubated for 5 min at 37°C with buffer or 10 µM
AR-C69931MX and challenged with the indicated concentrations of thrombin for 2 min at 37°C 
with stirring. Reactions were stopped by the addition of SDS-sample buffer. Samples were 
analyzed by SDS-PAGE followed by immuno(Western)blotting with sequential re-probing as 
described in “Materials and methods” using antibodies recognizing ERK1 and 2, dually 
phosphorylated at Tyr-185/Thr-183 (-YPTP), or unmodified ERK2. Shown result is from one 
experiment that is representative of 3 similar experiments.
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5.1.2 ERK2 activation in response to collagen 
Collagen is indispensable for platelet adhesion to the exposed endothelial 
matrix at sites of vascular injuries and is, besides thrombin, a strong agonist 
causing platelet activation and aggregation. Stimulating washed human 
platelets with collagen (1 and 10 µg/ml) provokes ERK2 activation following a 
time course similar to that observed with thrombin (Fig. 1; data not shown). 
 
5.1.2.1 Effect of precluding P2Y12 receptor signalling with 
AR-C69931MX on ERK2 activation 
To examine whether collagen-induced ERK2 activation is mediated by released 
ADP and subsequent P2Y12 receptor signalling platelets were preincubated 
with AR-C69931MX (10 µM) prior to stimulation with increasing concentrations 
of collagen (0.5, 1 and 10 µg/ml). Results are shown in Fig. 7.  
A concentration of 0.5 µg/ml collagen does not provoke detectable ERK2 
activation. Collagen at 1 µg/ml distinctly induces ERK2 activation that is 
completely abolished by AR-C69931MX. ERK2 activation in response to 
10 µg/ml collagen is still remarkably, but not entirely attenuated AR-C69931MX. 
 
Fig. 7   Effect of AR-C69931MX on ERK2 activation in response to increasing 
 concentrations of collagen 
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Washed human platelets were preincubated for 5 min at 37°C with buffer or 10 µM
AR-C 69931MX and challenged with the indicated concentrations of collagen for 2 min at 37°C 
with stirring. Reactions were stopped by the addition of SDS-sample buffer. Samples were 
analyzed by SDS-PAGE followed by immuno(Western)blotting with sequential re-probing as 
described in “Materials and methods” using antibodies recognizing ERK1 and 2, dually 
phosphorylated at Tyr-185/Thr-183 (-YPTP), or unmodified ERK2. Shown result is from one 
experiment that is representative of 3 similar experiments.
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As with thrombin (Fig. 5), ERK2 activation induced by collagen (1 and 10 µg/ml) 
is unaffected by pretreatment with the P2Y1 receptor antagonists A3P5P 
(500 µM) or MRS2179 (100 µM) (data not shown). 
 
 
5.1.2.2 Effect of precluding TXA2 signalling on ERK2 activation in 
response to collagen or thrombin 
Both collagen and thrombin, although initiating platelet activation via different 
signalling pathways, evoke the release of TXA2 that supports the effect of the 
initial stimulus leading to an enhanced secretion of ADP. 
To preclude TXA2-mediated signalling platelets were pretreated either with 
aspirin or with the TXA2-receptor antagonist SQ29548 prior to the addition of 
collagen or thrombin. 
As shown in Fig. 8A, preincubation with aspirin as well as with SQ29548 
abrogates the response to 10 µg/ml collagen and remarkably decrease the 
response to 50 µg/ml collagen. On the other hand (Fig. 8B), preventing TXA2 
signalling, whereas abrogating ERK2 activation provoked by 0.1 U/ml thrombin, 
has no effect when platelets are challenged with 0.3 U/ml thrombin. 
Thus far, the data indicate that ERK2 activation in response to both primary 
agonists thrombin and collagen strongly, albeit not exclusively, relies on 
released TXA2. Furthermore, ERK2 activation caused by thrombin as well as by 
collagen in the last instance relies on released ADP and P2Y12 receptor-
mediated Gi-coupling. 
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Fig. 8   Effects of aspirin and SQ29548 on ERK2 activation in response to 
               collagen and thrombin 
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Washed human platelets were pretreated with buffer, 1 mM aspirin for 30 min, or 10 and
100 µM SQ29548 for 5 min at 37°C with stirring and stimulated as indicated with collagen (A) or 
thrombin (B) for 2 min. Reactions were stopped by the addition of SDS-sample buffer. Samples 
were analyzed by SDS-PAGE followed by immuno(Western)blotting with sequential re-probing 
as described in “Materials and methods” using antibodies recognizing ERK1 and 2, dually 
phosphorylated at Tyr-185/Thr-183 (-YPTP) (A and B), and unmodified ERK2 (A), or ERK1 and 
2, respectively (B). Shown results are each from one experiment that is representative of 2 (A) 
and 3 (B) experiments.
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5.2 Effect of platelet-derived, secondary mediators on ERK2 
activation 
TXA2 and ADP, although provoking platelet activation and aggregation on their 
own, in vivo rather represent subsequent mediators as they are released from 
platelets usually as a consequence of primary stimulation by collagen or 
thrombin. 
 
5.2.1 ERK2 activation in response to TXA2-mimetic U46616 
The stable TXA2-mimetic U46619 applied at 10 µM provokes ERK2 activation 
peaking between 2 and 3 min of stimulation (data not shown), comparable to 
the time courses obtained for thrombin and collagen. 
 
5.2.1.1 Effects of P2Y receptor antagonists on U46619-induced ERK2 
activation 
As shown in Fig. 9, and similar to the effects observed in thrombin-stimulated 
platelets (Fig. 5), pretreatment with 10 µM AR-C69931MX entirely inhibits ERK2 
activation induced by 10 µM U46619, whereas 500 µM A3P5P and 100 µM 
MRS2179 have no effect. 
 
Fig. 9   Effects of P2Y receptor antagonists on U46619-evoked ERK2 activation 
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Washed human platelets were preincubated with buffer, 10 µM AR-C69931MX, 500 µM A3P5P, 
or 100 µM MRS2179 for 5 min at 37°C with stirring and stimulated with U46619 for
2 min. All samples contain 0.1 % ethanol as U46619-solvent control. Reactions were stopped 
by the addition of SDS-sample buffer. Samples were analyzed by SDS-PAGE followed by 
immuno(Western)blotting with sequential re-probing as described in “Materials and methods” 
using antibodies recognizing ERK1 and 2, dually phosphorylated at Tyr-185/Thr-183 (-YPTP), 
or unmodified ERK2. Shown result is from one experiment that is representative of 4 similar 
experiments.  
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5.2.1.2 Effect of a co-stimulation with U46619 and thrombin on ERK2 
activation 
ERK2 activation induced by 0.1 U/ml thrombin is dependent on intermediate 
TXA2 release and signalling (Fig. 8B) and both thrombin- and TXA2-provoked 
ERK2 activation depend on ADP release and subsequent P2Y12 receptor 
signalling (Figs. 5 and 9). To investigate this synergism in more detail platelets 
were incubated with subthreshold concentrations of thrombin and U46619 alone 
or in combination in the absence or presence of 10 µM AR-C69931MX. 
As shown in Fig. 10, U46619 at 0.1 µM and 1 µM alone does not provoke ERK2 
activation. On the other hand, in combination with 0.05 U/ml thrombin that alone 
likewise has no effect (Fig. 3), U46619 at 0.1 µM and more effectively at 1 µM 
provokes ERK2 activation that is sensitive to AR-C69931MX. 
 
Fig. 10   ERK2 activation provoked by combinations of subthreshold 
              concentrations of thrombin and U46619 
 
[Thrombin] (0.05 U/ml)  
[AR-C69931MX] (10 µM) 
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Washed human platelets were pretreated with buffer or 10 µM AR-C69931MX for 5 min at
37°C with stirring and stimulated with both thrombin or U46619 as indicated singly and in 
combination for 2 min. All samples contain 0.01 % ethanol as U46619-solvent control. 
Reactions were stopped by the addition of SDS-sample buffer. Samples were analyzed by 
SDS-PAGE followed by immuno(Western)blotting with sequential re-probing as described in 
“Materials and methods” using antibodies recognizing ERK1 and 2, dually phosphorylated at 
Tyr-185/Thr-183 (-YPTP), or unmodified ERK2. Shown result is from one experiment that is 
representative of 3 similar experiments.  
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5.2.2 Effect of ADP on ERK2 activation 
The data thus far suggest that TXA2 released in response to both collagen and 
thrombin synergizes with the signalling events of the initial stimulus by 
supporting ADP release and in turn consecutive P2Y12 receptor-mediated 
ERK2 activation. Interestingly, neither exogenously added ADP alone nor its 
more potent analogue 2-MeS-ADP, each applied up to 100 µM, are sufficient to 
provoke any detectable ERK2 activation (data not shown). 
 
5.2.2.1 Effect of 2-MeS-ADP on thrombin-evoked ERK2 activation 
The concentration of a primary agonist such as thrombin or collagen determines 
the amount of initially released ADP and, as such, the intensity of the 
subsequent amplifying effects of P2Y12 receptor signalling. 
If these limiting mechanisms also apply for ERK2 activation was tested by co-
stimulating platelets with increasing concentrations of both thrombin and 
2-MeS-ADP. 
As demonstrated in Fig. 11, in the presence of 0.05 U/ml thrombin that alone 
has no effect, the exogenously addition of 2-MeS-ADP at 10 µM and, more 
potently at 100 µM, provokes in ERK2 activation. This positive synergistic effect 
is also valid for ERK2 activation in response to 0.1 U/ml thrombin, but little or no 
amplification is detectable with 0.3 U/ml thrombin. 
 
Fig. 11   Effect of combinations of thrombin and 2-MeS-ADP on ERK2 activation 
 
[Thrombin] (U/ml)  0.05_ 0.05 0.05 0.1 0.1 0.1 0.3 0.3 0.3
_ [2-MeS-ADP] (µM)  _ 10 100 10 100 10 100_ _
Washed human platelets were stimulated with thrombin singly or in combination with 
2-MeS-ADP (as indicated) at 37°C for 2 min with stirring. Reactions were stopped by the 
addtion of SDS-sample buffer. Samples were analyzed by SDS-PAGE followed by 
immuno(Western)blotting with sequential re-probing as described in “Materials and Methods” 
using antibodies recognizing ERK1 and 2, dually phosphorylated at Tyr-185/Thr-183 (-YPTP), 
or unmodified ERK2. Shown result is from one experiment that is representative of 3 similar 
experiments.
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5.3 Mimicking P2Y12 ADP-receptor Gi-coupling by stimulating Gz-
coupled platelet α2A-adrenoceptors with epinephrine 
Epinephrine, acting on platelets via inhibitory G protein Gz-coupled 
α2A-adrenoceptors does not initiate activation of isolated platelets on its own, 
but potentiates platelet responses induced by other agonists.  
 
5.3.1 Effect of epinephrine on ERK2 activation induced by thrombin or 
U46619 and precluded P2Y12 ADP receptor signalling 
In accordance with previous studies, epinephrine-induced α2A-adrenoceptor 
signalling can mimic P2Y12 receptor-mediated platelet responses (Fig. 12). 
 
Fig. 12   Effect of epinephrine on ERK2 activation in thrombin- or U46619- 
 stimulated and AR-C69931MX-pretreated platelets 
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Washed human platelets were pretreated with buffer or 10 µM AR-C69931MX (AR-C) for 5 min 
at 37°C with stirring and stimulated as indicated with both epinephrine and thrombin (A) or 
U46619 (B) singly and simultaneously in combination for 2 min. All samples in B contain 0.1 % 
ethanol as U46619-solvent control. Reactions were stopped by the addition of SDS-sample 
buffer. Samples were analyzed by SDS-PAGE followed by immono(Western)blotting with 
sequential re-probing as described in “Materials and methods” using antibodies recognizing 
ERK1 and 2, dually phosphorylated at Tyr-185/Thr183 (-YPTP), or unmodified ERK1 and 2. 
Shown results are each from one experiment that is representative of 3 similar experiments.
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As shown in Fig. 12 A, epinephrine alone (1 and 10 µM) has no effect on ERK2 
activation. In contrast, epinephrine at 1 µM and more effectively at 10 µM 
enhances ERK2 activation in response to 0.1 U/ml thrombin. 
In addition, the inhibitory effect of 10 µM AR-C69931MX on ERK2 activation 
induced by 0.1 U/ml thrombin can be bypassed by 1 µM and 10 µM epinephrine 
in a concentration-dependent fashion. Similar results are obtained in platelets 
stimulated with 10 µM U46619 (Fig. 12 B) 
 
 
As demonstrated above, epinephrine, although alone is not able to evoke ERK2 
activation enhances the effect initially provoked by thrombin as well as by 
U46619. 
A more detailed analysis of this amplifying effect for thrombin-induced ERK2 
activation is shown in Fig. 13. 
 
Fig. 13   Effect of combinations of thrombin and epinephrine on ERK2 activation 
 
[Thrombin] (U/ml)  0.05_ 0.05 0.05 0.1 0.1 0.1 0.3 0.3 0.3
_ [Epinephrine] (µM) _ 1 10 1 10 1 10_ _
Washed human platelets were stimulated with as indicated thrombin alone or simultaneously in 
combination with epinephrine  at 37°C for 2 min with stirring. Reactions were stopped by the 
addition of SDS-sample buffer. Samples were analyzed by SDS-PAGE followed by 
immuno(Western)blotting with sequential re-probing as described in “Materials and methods” 
using antibodies recognizing ERK1 and 2, dually phosphorylated at Tyr-185/Thr-183 (-YPTP), 
or unmodified ERK1 and 2. Shown result is from one experiment that is representative of
3 similar experiments.
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ERK2 
ERK1 
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5.3.2 Effect of epinephrine on platelet aggregation induced by 
thrombin or U46619 under conditions of precluding P2Y12 ADP 
receptor signalling 
The ATP-analogues of the AR-C series such as AR-C69931MX and 
AR-C660096MX potently inhibit aggregation of washed human platelets in 
response to most, if not all, commonly known agonists, including thrombin 
(Fälker et al. 2005) , collagen (Roger et al. 2004), and U46619 (Paul et al. 
1999). 
The effect of epinephrine (1 and 10 µM) on aggregation of washed platelets 
pretreated with AR-C69931MX (10 µM) in response to thrombin (0.1 U/ml) is 
shown in Fig. 14. 
 
Fig. 14   Effect of epinephrine on platelet aggregation in thrombin-stimulated 
and AR-C69931MX-pretreated platelets 
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Washed human platelets were preincubated for 5 min with stirring at 37°C with buffer or 10 µM 
AR-C69931MX (AR-C) and challenged with 0.1 U/ml thrombin alone or simultaneously in 
combination with 1 and 10 µM epinephrine (Epi), respectively. Platelet aggregation was 
monitored as described in "Materials and methods“. Shown curves are from one experiment 
that is representative of 5 similar experiments.  
 
As expected, epinephrine alone (up to 100 µM) does not induce aggregation of 
washed human platelets (data not shown). 
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A statistical analysis of the 5 experiments of which one is presented in Fig. 14 
revealed that 0.1 U/ml thrombin induces maximal platelet aggregation of 
84±2%. Pretreatment with 10 µM AR-C69931MX decreases aggregation in 
response to thrombin to 11±4%. Epinephrine, when co-applied at 1 µM is able 
to recover the thrombin-response up to 66±8%, whereas 10 µM epinephrine 
entirely restores aggregation (82±2%). 
Regarding U46619-provoked aggregation of washed platelets comparable 
results were obtained. U46619 at 10 µM evokes maximal platelet aggregation of 
73±5% (n=6); pretreatment with 10 µM AR-C69931MX nearly entirely abrogates 
aggregation to 2±2% (n=6). Epinephrine is able to fully recover the U46619-
response when co-applied at 1 µM (75±6%; n=4). In combination with 10 µM 
epinephrine aggregation is regained to a minimum of 71% and maximum of 
75% (n=2). 
Ethanol at 0.1 % (v/v), as solvent control for U46619 were present in all 
samples and has no effect on platelet aggregation when added alone (data not 
shown). 
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5.4 Effect of integrin αIIbβ3 outside-in signalling on ERK2 activity 
Agonist-induced platelet activation leads to the conformational change and, as 
such, activation of integrin αIIbβ3. Fibrinogen binding, besides providing the 
molecular basis for platelet aggregation induces integrin αIIbβ3 outside-in 
signalling that has been demonstrated to regulate a variety of platelet 
responses and enhance platelet activation and aggregation (Parise 1999, 
Shattil et al. 2004). 
 
5.4.1 Effect of precluding fibrinogen-binding to integrin αIIbβ3 on ERK2 
activation provoked by thrombin 
Besides the RGDS peptide the non-peptide RGD mimetic S1197 was used for 
studying the effect of precluding fibrinogen binding to activated integrin αIIbβ3 on 
ERK2 activity. As shown in Fig. 15, both compounds markedly enhance ERK2 
activation induced by 0.1 U/ml thrombin. 
 
Fig. 15   Effect of RGDS and S1197 on ERK2 activation in response to thrombin 
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Washed human platelets were pretreated as indicated with buffer, AR-C69931MX (AR-C), 
RGDS, or S1197 for 5 min at 37°C with stirring and challenged with thrombin for 2 min. 
Reactions were stopped by the addition of SDS-sample buffer. Samples were analyzed by 
SDS-PAGE followed by immuno(Western) blotting with sequential re-probing as described in 
“Materials and methods” using antibodies recognizing ERK1 and 2, dually phosphorylated at 
Tyr-185/Thr-183 (-YPTP), or unmodified ERK1 and 2. Shown result is from one experiment that 
is representative of 3 similar experiments.  
 
As expected, platelet aggregation in response to 0.1 U/ml thrombin is 
completely abolished by RGDS (500 µM) as well as S1197 (1 µM) (data not 
shown). 
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5.4.2 Effect of S1197 on the time course of thrombin-induced ERK2 
activation 
To further investigate the effect of integrin αIIbβ3 outside-in signalling on ERK2 
activity a time course was performed stimulating platelets with 0.1 U/ml 
thrombin in the presence of 1 µM S1197. 
As shown in Fig. 16, in the presence of S1197 the activation of ERK2 in 
response to thrombin is not accelerated but markedly enhanced. 
 
Fig. 16    Effect of S1197 on the time course of ERK2 activation in response 
                 to thrombin 
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Washed human platelets were pretreated with buffer or 1 µM S1197 for 5 min at
37°C with stirring and challenged with 0.1 U/ml thrombin (Thr) or buffer for control for the 
indicated times. Reactions were stopped by the addition of SDS-sample buffer. Samples were 
analyzed by SDS-PAGE followed by Western blotting with sequential re-probing as described in 
“Materials and methods” using identical dilutions of antibodies for both NCs, respectively. 
Applied antibodies recognize ERK1 and 2, dually phosphorylated at Tyr-185/Thr-183 (-YPTP), 
or unmodified ERK2. NCs were simultaneously exposed to X-ray films. Shown result is from 
one experiment that is representative of 2 similar experiments.  
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5.5 Signalling pathways downstream the P2Y12 ADP receptor 
involved in ERK2 activation 
Stimulation of the Gi2-coupled P2Y12 receptor by ADP induces the activation 
and therefore dissociation of Gi α- and β/γ-subunits. Whereas αi-subunits cause 
the inhibition of adenylyl cyclase, the β/γ-subunits have been demonstrated to 
activate phosphoinositide 3-kinase (PI 3-K). 
 
5.5.1 Effect of the direct inhibition of adenylyl cyclase on ERK2 
activation 
Whether the direct inhibition of adenylyl cyclase is sufficient to restore the 
effects of AR-C69931MX on P2Y12 receptor-mediated Gi2 α-subunit signalling 
was investigated. Platelets were incubated with either 10 µM 
AR-C69931MX or 500 µM SQ22536, an adenosine analogue that potently 
blocks adenylyl cyclase activity, alone or in combination prior to the stimulation 
with 0.1 U/ml thrombin. 
As demonstrated in Fig. 17, SQ22536 neither recovers the inhibitory effects of 
AR-C69931MX on thrombin-induced ERK2 activation nor affects the single 
thrombin response. 
 
Fig. 17   Effect of SQ22536 on thrombin-induced ERK2 activation in 
   AR-C69931MX-pretreated platelets 
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Washed human platelets were pretreated with buffer, 500 µM SQ22536, 10 µM AR-C69931MX 
or both for 5 min at 37°C with stirring and challenged with thrombin or buffer for 2 min,
respectively. Reactions were stopped by the addition of SDS-sample buffer. Samples were 
analyzed by SDS-PAGE followed by immuno(Western)blotting with sequential re-probing as 
described in “Materials and methods” using antibodies recognizing ERK1 and 2, dually 
phosphorylated at Tyr-185/Thr-183 (-YPTP), or unmodified ERK2. Shown result is from one 
experiment that is representative of 2 similar experiments.
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5.5.2 Effect of the inhibition of phosphoinositide 3-kinase (PI 3-K) on 
thrombin-induced ERK2 activation 
To determine whether PI 3-K activity contributes to P2Y12 receptor-dependent 
ERK2 activation platelets were incubated with the two structurally unrelated 
PI 3-K inhibitors wortmannin and LY294002 prior to thrombin-stimulation. 
The effects of LY294002 and wortmannin on ERK2 activation provoked by 
thrombin are shown in Fig. 18. 
 
Fig. 18   Effects of LY294002 and wortmannin on ERK2 activation induced by 
                thrombin 
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[LY294002] (µM)_
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Washed human platelets were pretreated with buffer, LY294002 or wortmannin as indicated for 
15 min at 37°C with stirring and stimulated with thrombin for 2 min. All samples contain 0.25 %
DMSO as solvent control. Reactions were stopped by the addition of SDS-sample buffer. 
Samples were analyzed by SDS-PAGE followed by immuno(Western)blotting with sequential 
re-probing as described in “Materials and methods” using antibodies recognizing ERK1 and 2, 
dually phosphorylated at Tyr-185/Thr-183 (-YPTP), or unmodified ERK1 and 2. Shown result is 
from one experiment that is representative of 3 similar experiments.
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Both PI 3-K inhibitors attenuate ERK2 activation caused by thrombin in a 
concentration-dependent fashion. LY294002 at 10 and more potently at 50 µM 
as well as wortmannin at 0.1 and, most efficiently at 1 µM prevent ERK2 
activation in response to 0.1 U/ml thrombin. 
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5.5.3 Effects of the inhibition of the MAP/ERK kinases 1 and 2 
(MEK1/2) on ERK2 activation evoked by thrombin 
ERK1 and 2 both become activated by the dual-specific MAPK/ERK kinases 1 
and 2 (MEK1/2). 
Two commonly used pharmacologically unrelated MEK1/2 inhibitors were 
applied within this work, the organic compound U0126 and the synthetic flavone 
compound PD98059. 
ERK2 activation provoked by 0.1 U/ml thrombin is effectively attenuated by 
1 µM and almost completely inhibited by 3 µM U0126, whereas PD98059, to 
achieve comparable effects, is required at higher concentrations of 3 µM and 
10 µM, respectively (Fig. 19). 
 
Fig. 19   Effects of U0126 and PD98059 on thrombin-induced ERK2 activation 
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Washed human platelets were pretreated with buffer or U0126 and PD98059 as indicated for 30 
min at 37°C with stirring and stimulated with thrombin for 2 min. All samples contain 0.05% 
DMSO as solvent control. Reactions were stopped by the addition of SDS-sample buffer. 
Samples were analyzed by SDS-PAGE followed by immuno(Western)blotting with sequential 
re-probing as described in “Materials and methods” using antibodies recognizing ERK1 and 2, 
dually phosphorylated at Tyr-185/Thr-183 (-YPTP), or unmodified  ERK1 and 2. Shown result is 
from one experiment that is representative of 3 similar experiments.
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1 3 10___
+ + +
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5.5.4 Akt (protein kinase B) phosphorylation at Ser-473 in response to 
thrombin 
In thrombin-stimulated washed human platelets the serine/threonine kinase Akt, 
also designated protein kinase B (PKB), gets activated in a P2Y12 receptor/ 
PI 3-K-dependent manner (Kim et al. 2004). Besides its translocation to the cell 
membrane, independent phosphorylation of Akt at both Thr-308 and Ser-473 
residues are required for full enzyme activity (Alessi et al. 1996). Akt Thr-308 
residues are phosphorylated by the phosphatidylinositol-dependent kinase 1 
(PDK1), whereas the kinase which phosphorylates Ser-473 is yet unidentified. 
 
5.5.4.1 Time course of thrombin-induced Akt Ser-473 phosphorylation 
The time course of Akt phosphorylation at Ser-473 compared to ERK2 
activation in platelets stimulated with 0.1 U/ml thrombin is shown in Fig. 20. 
In unstimulated platelets, Akt is not, or in some experiments only marginally, 
phosphorylated. Upon thrombin stimulation, Akt phosphorylation is detectable 
within 30 sec, increases within 6 min and remains phosphorylated up to 10 min, 
demonstrating the Akt activation lags behind that of ERK2. 
 
Fig. 20    Time course of Akt serine phosphorylation and ERK2 activation 
 provoked by thrombin 
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Washed human platelets were incubated with 0.1 U/ml thrombin (Thr) for the indicated times
at 37°C with stirring. Reactions were stopped by the addition of SDS-sample buffer. Samples 
were analyzed by SDS-PAGE followed by immuno(Western)blotting with sequential re-probing 
as described in “Materials and methods” using antibodies recognizing Akt, phosphorylated at
Ser-473 residues (-SP), ERK1 and 2, dually phosphorylated at Tyr-185/Thr-183 (-YPTP), or 
unmodified ERK2. Shown result is from one experiment that is representative of 4 similar 
experiments.  
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The time-dependent changes of Akt phosphorylation at Ser-473 compared to 
that of ERK2 at Tyr-185/Thr-183 were quantified by densitometric analysis 
(Fig. 21). 
 
Fig. 21   Quantification of the time-dependent changes in phosphorylation of Akt 
  at Ser-473 and ERK2 at Tyr-185/Thr183 upon thrombin-stimulation 
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X-ray films from the 4 immuno(Western)blots, of which one is shown in Fig. 20, were 
densitometrically analyzed as described in “Materials and methods”. Data were processed by 
setting the maximal optical intensity of the respective band as 100% and are means±S.E.M.
Error bars are not shown for data points having error that is smaller than the symbol. The graph 
shows Akt Ser-473 phosphorylation (Akt-SP) as well as ERK2 dually phosphorylated at
Tyr-185/Thr-183 (ERK2-YPTP).  
 
 
5.5.4.2 Effects of inhibitors of PI 3-Kinase and of MEK1/2 on Akt Ser-473 
phosphorylation provoked by thrombin 
The effects of the PI 3-K inhibitors LY294002 and wortmannin, as well as of the 
MEK1/2 inhibitors U0126 and PD98059 on thrombin-evoked Akt Ser-473 
phosphorylation are shown in Fig. 22. 
Akt Ser-473 phosphorylation induced by 0.1 U/ml thrombin is effectively 
inhibited by the two PI 3-K inhibitors. LY294002 potentially prevents Akt 
phosphorylation at 10 µM and completely abrogates phosphorylation at 50 µM 
whereas wortmannin totally blocks Akt phosphorylation already at 0.1 µM.  
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Fig. 22   Effects of LY294002 and wortmannin as well as U0126 and PD98059 
    on Akt Ser-473 phosphorylation induced by thrombin 
 
[PD98059] (µM)  
[U0126] (µM)_
Akt-SP
ERK2 
__
[Thrombin] (0.1 U/ml)  _ + + + +
Washed human platelets were pretreated with buffer, or increasing concentrations of LY294002 
and wortmannin as indicated for 30 min, or buffer, and U0126 or PD98059 for 15 min, 
respectively, at 37°C with stirring and challenged with thrombin for 6 min. All samples contain 
0.25 % DMSO as solvent control. Reactions were stopped by the addition of SDS-sample 
buffer. Samples were analyzed by SDS-PAGE followed by immuno(Western)blotting with 
sequential re-probing as described in “Materials and methods” using antibodies recognizing Akt
phosphorylated at Ser-473 (-SP) or unmodified ERK2. Shown result is from one experiment that
is representative of 3 similar experiments.
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The MEK1/2 inhibitors U0126 and PD98059 (both at 10 µM), in contrast to their 
ability to prevent ERK2 activation (Fig. 19), do not have any effect on thrombin-
provoked Akt phosphorylation at Ser-473. 
 
 
5.6 Involvement of ERK2 in primary functional responses associated 
with platelet activation 
Agonist-induced platelet activation, as aforementioned, strongly relies on the 
release of positive feedback mediators, such as TXA2 and ADP. These platelet-
derived mediators support and enhance the primary signal leading, besides 
other platelet responses, to the secretion of α- and dense granules and to the 
activation of integrin αIIaβ3 as the prerequisite for final platelet aggregation. 
Therefore, an involvement of ERK2 in these events accompanying primary 
platelet activation was addressed. 
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5.6.1 Effects of MEK1/2 inhibitors on α- and dense granule release in 
response to thrombin 
P-selectin, also termed CD62, is localized in the membrane of 
α-granules of resting platelets and serves as a marker for α-granule release 
from activated platelets when exposed on the plasma membrane. 
Platelet dense granules contain, besides ADP and ATP, serotonin 
(5-hydroxytryptamine; 5-HT).  
The time-courses of thrombin-induced platelet α-granule secretion, determined 
by P-selectin expression, and the release of dense granule contents, 
determined by 5-HT-release, are presented in Fig. 23. 
 
Fig. 23  Quantification of the time course of platelet CD62 exposure and 
[3H]5-HT release provoked by thrombin 
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Washed human platelets were challenged with 0.1 U/ml thrombin for the indicated times. 
Platelet [3H]5-HT release and CD62 expression were monitored as described in “Materials and 
methods”. Data are means±S.E.M. and error bars are not shown for data points having error 
that is smaller than the symbol. Shown curves are each from 4 experiments.  
 
Upon stimulation with 0.1 U/ml thrombin α-granule secretion is completed up to 
89±3 % within 1 min after the onset of stimulation. 5-HT from dense granules is 
released within 1 min up to 70±3 %, and the maximal determined release of 
81±1 %is assessed after 2 min. 
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Pretreatment with U0126 or PD98059, both at 10 µM, does not have any effect 
on α-granule secretion (determined by CD62 expression; n=3; data not shown). 
On the other hand, the release of [3H]5-HT from dense granules evoked by 
0.1 U/ml thrombin determined after 2 min of stimulation is attenuated about 
9±5 % by 10 µM U0126 (p=0,18; n=3) and 16±9 % by 10 µM PD98059 (p=0,03; 
n=3). DMSO, present in all samples at 0.05 % (v/v) as solvent control for U0126 
and PD98059, has no effect. 
 
 
5.6.2 Effects of MEK1/2 inhibitors on thrombin-provoked integrin αIIbβ3 
activation and platelet aggregation 
The monoclonal antibody PAC-1 binds exclusively to activated integrin αIIbβ3 
and is consentiently accepted as a quantitative marker for integrin αIIbβ3 
activation by flow cytometric analysis (Schmitz et al. 1998). The time courses of 
PAC-1 binding and platelet aggregation in response to thrombin are shown in 
Fig. 24. 
 
Fig. 24   Quantification of the time courses of thrombin-induced PAC-1 binding 
and platelet aggregation 
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Washed human platelets were stimulated with 0.1 U/ml thrombin for the indicated times.
PAC-1 binding and platelet aggregation were monitored as described in “Materials and 
methods”. Data are means±S.E.M. and error bars are not shown for data points having error 
that is smaller than the symbol. Shown curve for PAC-1 binding is from 4 and that for platelet 
aggregation from 6 experiments, respectively.  
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The data reveal that after 30 sec of stimulation with 0.1 U/ml thrombin the 
activation of integrin αIIbβ3 (PAC-1 binding) is already completed up to 80±11 %; 
the maximal response of 92±3 % was determined as after 3 min. 
Platelet aggregation induced by thrombin reaches about 46±3 % after 1 min, 
and 68±3 % after 2 min of stimulation. Maximal platelet aggregation of 82±2 % 
is reached after 4 to 5 min. 
 
Whether ERK2 contributes to integrin αIIbβ3 activation or/and platelet 
aggregation was investigated by pretreating platelets with 10 µM PD98059 or 
U0126, respectively, prior to the stimulation with 0.1 U/ml thrombin. DMSO, as 
solvent control for U0126 and PD98059 was present in all samples at 0.05 % 
(v/v), and had no effect. 
Both inhibitors do not have any effect on neither integrin αIIbβ3 activation 
(PAC-1 binding) nor the velocity or amplitude of platelet aggregation in 
response to 0.1 U/ml thrombin (data not shown). 
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6 DISCUSSION 
 
 
6.1 ERK2 activation in response to the primary platelet agonists 
thrombin and collagen 
 
6.1.1 Gq-mediated signalling induced by thrombin initiates ADP 
secretion and ERK2 activation which is amplified by Gi-coupled 
P2Y12 ADP receptor signalling 
Thrombin, on of the most potent primary platelet agonist induces the activation 
and aggregation of human platelets via the two Gq-coupled protease-activated 
receptors (PARs) 1 and 4 (Kahn et al. 1999). 
In isolated human platelets thrombin has been shown to induce ERK2 activation 
in a time- and concentration-dependent manner (Papkoff et al. 1994, 
Nakashima et al. 1994, Nadal et al. 1997). The precise signalling mechanisms 
involved, however, have not yet been elucidated. 
Within this thesis it could be demonstrated that the release of ADP and 
subsequent P2Y12 ADP receptor signalling are crucial events amplifying 
thrombin- as well as collagen-induced ERK2 activation. 
A detailed analysis of the two phosphorylation steps of ERK2 in thrombin-
stimulated washed human platelets (Figs. 1, 2) revealed that initial Thr-185 
phosphorylation occurs within 30 sec, whereas the dual-phosphorylated active 
state is not detectable until 1 min after the onset of stimulation. ERK2 activity 
peaks between 2 to 3 min and decreases subsequently. Comparing the course 
of ERK2 deactivation, which will be discussed below (chapter 6.3), reveals that 
dephosphorylation of threonine-residues precedes that of tyrosine-residues. 
The importance of released ADP for thrombin-induced ERK2 activation was 
implied by the use of apyrase, which scavenges released adenine nucleotides 
(Fig. 4). 
The use of specific P2Y ADP receptor antagonists allows to differentiate 
between the receptor subtypes involved and revealed that P2Y12 receptors but 
not P2Y1 receptors mediate the effect of released ADP (Fig. 5). AR-C69931MX, 
a highly specific, competitively acting P2Y12 receptor antagonist, completely 
abolishes ERK2 activation in response 0.1 U/ml thrombin. 
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ERK2 activation induced by higher thrombin concentrations (0.3 U/ml) is still 
effectively but not completely inhibited by AR-C69931MX (Fig. 6), strongly 
indicating that an ADP-independent mechanism comes into play under these 
conditions. This mechanism might involve protein kinase C (PKC)- and calcium-
dependent pathways, which have previously been demonstrated to mediate 
ERK2 activation in thrombin-stimulated platelets (Börsch-Haubold et al. 1995, 
Nadal-Wollbold et al. 2002), suggesting that under these conditions Gq-
mediated pathways predominate over P2Y12 ADP receptor-induced Gi-
signalling. 
 
6.1.1.1 Thrombin and released TXA2 synergizes in Gq-signalling evoked 
ADP release 
Besides ADP, TXA2 is released from activated platelet and both mediators 
support and enhance the platelet response to the initial stimulus. 
Human platelets contain mRNA encoding both the thromboxane / prostanoid 
receptor alpha and beta subtypes (TPα and TPβ), which couple to Gq- and Gi-
proteins, respectively (Hirata et al. 1996). In 1999, Habib et al. demonstrated 
that the TPα receptor is the predominant isoform expressed on human platelets. 
Indeed, TXA2-mimetic U46619-induced inhibition of adenylyl cyclase and 
platelet aggregation depends upon secretion of ADP and subsequent P2Y12 
ADP receptor signalling (Paul et al. 1999). U46619 has also been demonstrated 
to induce ERK2 activation in rabbit and human platelets (Ohkubo et al. 1996, 
McNicol et al. 2001). 
Like thrombin, U46619 provokes ERK2 activation in a P2Y12 receptor- but not 
P2Y1 receptor-dependent manner (Fig. 9; Fälker et al. 2004, Roger et al. 2004). 
Thrombin and released TXA2 act through G protein-coupled receptors that in 
turn activate Gq as well as G12/13 (Offermanns et al. 1994). In platelets from 
Gq-deficient mice, coordinated signalling through G12/13 and Gi proteins has 
been demonstrated to be sufficient for integrin αIIbβ3 activation and platelet 
aggregation (Nieswandt et al. 2002, Dorsam et al. 2002). In contrast, for 
granules secretion, Gq-induced signalling pathways are required (Offermanns 
et al. 1997). Low concentrations of U46619 induce calcium mobilization and 
platelet shape change via G12/13, whereas at higher U46619 concentrations 
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Gq-coupled signalling causes ADP release and, in turn, P2Y12 receptor-
dependent platelet aggregation (Paul et al. 1999). The observation that 
U46619-induced ERK2 activation is mediated by P2Y12 receptor signalling 
allows the conclusion that Gq-mediated ADP secretion precedes ERK2 
activation. 
The data suggest that Gq signalling, either induced by thrombin or by U46619, 
is the initial and determining step for ERK2 activation, which in turn is amplified 
by concomitant ADP release and P2Y12 receptor-mediated Gi-signalling. 
This raised the question to what extent released TXA2 is involved in or 
contributes to ERK2 activation induced by thrombin. 
Subthreshold concentrations of thrombin and U46619 alone have no effect, 
whereas a co-stimulation provokes ERK2 activation sensitive to 
AR-C69931MX (Fig. 10). In addition, precluding TXA2 signalling either by 
preventing TXA2 synthesis with aspirin or by pretreatment with the TXA2 
receptor antagonist SQ29548 has no effect on ERK2 activation evoked by high 
concentrations of thrombin (0.3 U/ml), whereas the response to 0.1 U/ml 
thrombin is almost completely inhibited (Fig. 8B).  
These results provide evidence that released TXA2 synergizes thrombin-
induced ERK2 activation by amplifying initial Gq signalling resulting in enhanced 
ADP release and subsequent P2Y12 receptor signalling. This synergism, on the 
other hand, is obviously not required at high concentrations of thrombin. 
 
6.1.2 Cooperative Gq- and Gi-signalling is required for collagen-
induced ERK2 activation 
Collagen is the most thrombogenic component of the subendothelial matrix. 
Following vascular damage, collagen is exposed to and induces the activation 
of circulating platelets. Mainly two receptors are involved in the platelet 
response to collagen; integrin α2β1 acts to adhere platelets to collagen, allowing 
platelets to interact with the lower affinity receptor glycoprotein VI (GP VI), 
which is for the most part responsible for platelet activation. GP VI, a member of 
the immunoglobulin (Ig) receptor superfamily, builds a complex with the 
Fc receptor (FcR) γ-chain. The signal induced by collagen via GP VI is 
transduced through a FcR γ-chain-mediated tyrosine phosphorylation cascade 
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involving the Src kinase family members Lyn and Fyn, leading to the activation 
of phospholipase C isoform γ2 (PLCγ2). Although collagen initiates the 
activation of platelets, the release of TXA2 and ADP as well as thrombin-
generation are required for full platelet aggregation and thrombus formation (for 
review see Nieswandt et al. 2003). 
Besides thrombin, collagen has been reported to provoke ERK2 activation in 
human platelets (Börsch-Haubold et al. 1995). 
Previous studies by Oury et al. (2002) suggest that ERK2 activation induced by 
low concentrations of collagen (1 µg/ml) is mediated by released ATP and 
ionophoric P2X1 receptors in an calcium- and PKC-dependent manner. The 
authors further reported that this effect can be abolished by antagonizing the 
P2X1 receptors with ADP. 
This report contradicts the presented finding that ERK2 activation induced by 
1 µg/ml collagen is completely inhibited by 10 µM AR-C69931MX (Fig. 7), 
indicating that released ADP acts rather supportive than inhibitory. Although it 
cannot be excluded that the observed inhibitory effect might be due to 
antagonistic actions of released ADP on P2X1 receptors, the amount of 
apyrase, which scavenges ADP, applied during platelet preparation within this 
work is not sufficient to protect platelet P2X1 receptors from desensitization 
(see the “Materials and methods” section 4.2, and Cazenave et al. 2004). 
In addition, ERK2 activation provoked by moderate concentrations of collagen 
(10 µg/ml) is also markedly decreased by AR-C69931MX (Fig. 7). 
The data correspond with the observations by Roger et al. (2004), who 
additionally demonstrated that desensitizing P2X1 receptors with α,β-MeATP 
has no effect on ERK2 activation in response to 10 µg/ml collagen. The authors 
further showed, in absolute agreement and support with the data presented in 
Fig. 8A, that intermediate TXA2 signalling is required for ERK2 activation 
provoked by 10 mg/ml collagen. 
However, at high concentrations of collagen (50 µg/ml) ERK2 activation is still 
remarkably but not entirely dependent on TXA2 signalling (Fig. 8A).  
Collagen and convulxin, a component of the venom of the tropical rattlesnake 
(Crotalus durissus terrificus), induce via GP VI the activation of integrin αIIbβ3 by 
unrelated PKC- and calcium-regulated pathways. These pathways are 
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supported by, but do not strictly dependent on secreted TXA2 and/or ADP 
(Quinton et al. 2002, Atkinson et al. 2001). 
Thus, like in thombin-stimulated platelets (Börsch-Haubold et al. 1995, Nadal-
Wollbold et al. 2002), the observed effects might by explained by a PKC- and/or 
calcium-mediated activation of ERK2. 
 
 
6.2 Gi-mediated signalling alone is not sufficient to induce ERK2 
activation 
 
6.2.1 ADP does not evoke ERK2 activation but amplifies the Gq-
mediated response to thrombin 
The presented data thus far clearly demonstrate that released ADP and 
subsequent P2Y12 receptor-mediated Gi signalling is necessarily required for 
ERK2 activation in response to low concentrations of thrombin and collagen, 
whereas this contributing effect becomes less important at higher 
concentrations of both primary agonists. 
This regulatory principle had on a molecular level first been reported for 
thrombin-induced platelet phospholipase D (Martinson et al. 1998). 
Neither exogenously added ADP nor its more potent analogue 2-MeS-ADP, 
however, have any detectable effect on ERK2 activation (data not shown), 
which agrees with previous observations by Oury et al. (2002) and in part with 
those by Roger et al. (2004) reporting no or little ERK2 phosphorylation induced 
by 2-MeS-ADP. 
These findings indicate that the cooperation of P2Y1 receptor-mediated Gq 
coupling and P2Y12 receptor-mediated Gi signalling is not sufficient to evoke 
ERK2 activation. P2Y1 receptors are considered to induce only weak Gq 
signalling due to the relatively small amount of approximately 150 P2Y1 
receptors per platelet, which is very low as compared with the TPα TXA2 
receptors or the PAR1 thrombin receptors (both 1000-2000 receptors/platelet) 
(Hechler et al. 2005). 
In combination with 0.05 U/ml thrombin, that alone has no effect, 
2-MeS-ADP evokes ERK2 activation in a concentration-dependent fashion (Fig. 
11). This amplifying effect is also valid for ERK2 activation induced by 0.1 U/ml 
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thrombin, but becomes less prominent at a concentration of 0.3 U/ml. This 
finding suggests that the amount of endogenous ADP released at higher 
concentrations of thrombin is sufficient to support maximal ERK2 activation. 
Thus far, the data provide evidence that ERK2 activation appears not to be 
simply the consequence of cooperative Gq- and Gi-signalling, but that the 
quality and/or intensity of the initial Gq-signal critically determines the amplifying 
capacity of the subsequent Gi-signalling. 
 
6.2.2 P2Y12 ADP receptor coupling to Gi can be mimicked by 
stimulating α2A-adrenoceptors with epinephrine 
To further focus on the significance of Gi signalling, platelets were stimulated 
with epinephrine (adrenaline). On platelets epinephrine acts mainly via 
α2A-adrenergic receptors coupling to an inhibitory G protein that have been 
identified as Gz (Yang et al. 2000). In isolated human platelets epinephrine 
potentiates platelet activation but is not an agonist by itself (Lanza et al. 1988, 
Steen et al. 1993). Along this line it has been demonstrated that epinephrine is 
able to mimic and amplify ADP-induced activation of washed human platelets 
from volunteers after ticlopidine administration (Gachet et al. 1990). In addition, 
platelets isolated from epinephrine "nonresponders" also showed an impaired 
response to ADP, strongly suggesting that both α2A-adrenoceptors and P2Y12 
purinoceptors share intracellular pathways (Nakahashi et al. 2001). 
As expected, epinephrine alone has neither any effect on ERK2 activation (Fig. 
12 A and B) nor on platelet aggregation (data not shown). 
By contrast, in combination with low concentrations of thrombin (0.05 U/ml), that 
alone has no effect, epinephrine is able to evoke ERK2 activation. The 
enhancing effect of epinephrine is attenuated at higher concentrations of 
thrombin (Fig. 13). Furthermore, epinephrine is able to abrogate the inhibitory 
effect of AR-C69931MX on ERK2 activation in response to thrombin and 
U46619 (Figs. 12 A and B) as well as on platelet aggregation (Fig. 14).  
Regarding thrombin-induced ERK2 activation, as well as platelet aggregation, 
the data demonstrate that P2Y12 ADP receptor coupling to Gi can be mimicked 
by stimulating α2A-adrenoceptors with epinephrine.  
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Likewise, it has been previously reported that epinephrine is able replace ADP 
in terms of platelet PI 3-K activation (Selheim et al. 2000) and PI 3-K-dependent 
integrin αIIbβ3 activation (Kauffenstein et al. 2001). 
That the effect of epinephrine on ERK2 activation is mediated by inhibitory Gz-
coupled α-adrenergic receptors has been positively tested by challenging 
AR-C69931MX-pretreated and thrombin-stimulated platelets with isoproterenol 
(10 µM). Isoproterenol selectively stimulates platelet β2-adrenergic Gs-coupled 
receptors. In contrast to epinephrine, isoproterenol is not able to recover ERK2 
activation or platelet aggregation (data not shown). In addition, and as 
described previously, isoproterenol attenuates thrombin-induced platelet 
aggregation due to an increase of cAMP (Mills et al. 1971, Kerry et al. 1983). 
 
As AR-C69931MX potently inhibits thrombin-induced platelet aggregation (Fig. 
14, Fälker et al. 2005) one might argue that the attenuation of ERK2 activation 
is simply due to the inhibition of platelet aggregation. Under conditions of 
thrombin-induced platelet activation with precluding aggregation by preventing 
fibrinogen binding to integrin αIIbβ3 with the tetrapeptide RGDS or the non-
petidergic S1197, the activity of ERK2 is markedly enhanced (Figs. 15 and 16, 
discussed below in 6.3). Therefore, the inhibitory effect of 
AR-C69931MX on thrombin-stimulated ERK2 activation cannot be due to 
indirect actions of the antagonist on integrin αIIbβ3 outside-in signalling, which 
itself is inhibitory to ERK2 activation. 
 
Taken together, the observation that neither ADP nor epinephrine alone 
activates ERK2 but both are able to amplify the response to thrombin and the 
TXA2-mimetic U46619 indicate that Gi-coupling alone is not sufficient to 
provoke ERK2 activation; a quantitatively-regulated cooperation of initial Gq as 
well as subsequent Gi signalling is required. 
Furthermore, the findings support the suggestion that the amplifying effects of 
Gi signalling are in the first instance determined by the intensity of the initial Gq 
signal. 
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6.3 ERK2 activity is regulated by integrin αIIbβ3 outside-in signalling 
In several cell types such as fibroblasts, endothelial cells, and osteoblasts 
integrin-mediated signalling causes the activation of the ERK cascade (Chen Q. 
et al. 1994, Ishida et al. 1996, Schmidt et al. 1998).  
In contrast, and most noteworthy, by preventing fibrinogen binding to platelet 
integrin αIIbβ3 with the tetrapeptide RGDS or by the use of platelets from 
patients with Glanzmann’s thrombasthenia (which lack functional integrin αIIbβ3 
complexes) it has been demonstrated that integrin αIIbβ3 outside-in signalling 
down-regulates ERK2 activity (Nadal et al. 1997, Bugaud et al. 1999).  
This negative regulation has further been reported to be mediated via an 
unknown cytosolic serin/threonine phosphatase by selective dephosphorylation 
of Thr-183, whereas the regulation of Tyr-185 phosphorylation does not engage 
integrin αIIbβ3 signalling (Pawlowski et al. 2002). 
Several antagonists of the integrin αIIbβ3, such as the RGDS peptide, couple to 
the fibrinogen-binding motif (RGD) within the integrin α-subunit and, although 
precluding platelet aggregation, exert intrinsic properties and are therefore able 
to induce outside-in signalling (Du et al. 1991). 
Besides RGDS, the non-peptide RGD mimetic S1197 has been used (Stilz et al. 
2001). Due to its chemical composition, this compound is considered not to 
bear intrinsic features. S1197, similar to RGDS, markedly enhances ERK2 
activation in response to thrombin (Fig. 15), supporting and broaden the above 
mentioned reports (Nadal et al. 1997, Bugaud et al. 1999). 
The time-course of thrombin-induced ERK2 activity in S1197-pretreated 
platelets (Fig. 16) reveals that ERK2 deactivation is inhibited and delayed but 
not entirely abrogated, suggesting that besides integrin αIIbβ3 outside-in 
signalling other pathways may mediate ERK2 dephosphorylation. 
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6.4 Gi β/γ-subunit-induced phosphoinositide 3-K activity mediates 
ERK2 activation downstream of the P2Y12 ADP receptor 
It is well established that P2Y12 receptor Gi2-coupling affects adenylyl cyclase 
via Gi α-subunits and induces activation of PI 3-K isoforms via Gi β/γ-subunits 
(Dorsam et al. 2004, Hechler et al. 2005). The precise mechanisms for the Gi-
mediated potentiation of platelet responses, however, are yet not fully 
understood. 
Neither ADP nor epinephrine, in contrast to their ability to inhibit PGI2-induced 
adenylyl cyclase activity, have been found to cause a decrease in basal cAMP 
levels (Savi et al. 1996, Yang et al. 2002). 
The adenosine analogue SQ22536 potently blocks adenylyl cyclase activity in 
intact human platelets (Haslam et al. 1978a). The direct inhibition of adenylyl 
cyclase by SQ22536 or 2', 5'-dideoxyadenosine exerts pro-aggregatory effects 
only when cAMP levels were pre-elevated by PGI2, but does neither induce 
platelet aggregation on its own nor potentiates agonist-induced platelet 
responses (Haslam et al. 1978b). In addition, the negative regulation of adenylyl 
cyclase alone has been reported not to be able to replace neither P2Y12 
receptor nor α2A-adrenoceptor signalling (Savi et al. 1996, Yang et al. 2002, 
Daniel et al. 1999). The inhibition of adenylyl cyclase, as such, is not considered 
to be directly involved in platelet activation but to be required to counteract anti-
aggregatory effects of mediators causing elevation of cAMP. 
P2Y12 receptor-mediated activation of PI 3-K, on the other hand, induces 
and/or potentiates the activation of Rap1B (Lova et al. 2003), Akt (Kim et al. 
2004), as well as secretion of dense granule contents (Dangelmaier et al. 
2001), activation of integrin αIIaβ3 (Kauffenstein et al. 2001) and finally platelet 
aggregation (Trumel et al. 1999).  
Regarding the negative regulation of adenylyl cyclase we have just recently 
been able to demonstrate that SQ22536, at a concentration that maximally 
blocks forskolin-induced adenyly cyclase (Daniel et al. 1999), is able to 
abrogate inhibitory effects of AR-C69931MX on thrombin-induced tyrosine 
phosphorylation of unidentified proteins with apparent molecular masses of 27 
and 31 kDa (Fälker et al. 2005).  
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However, SQ22536 has no effect on ERK2 activation on its own nor 
circumvents the inhibitory effect of AR-C69931MX on thrombin-provoked ERK2 
activation (Fig. 18). 
On the other hand, the two structurally unrelated PI 3-K inhibitors LY294002 
and wortmannin prevent thrombin-induced ERK2 activation in a concentration-
dependent fashion (Fig. 19). These data contradict previous findings by Nadal-
Wollbold et al. (2002) negotiating an involvement of PI 3-K in ERK2 activation in 
response to thrombin. Within their studies the authors used lower 
concentrations of LY294002 (25 µM) and wortmannin (50 nM) and stimulated 
with 1 U/ml thrombin. Especially the use of the high concentration of thrombin 
might lead to the misinterpretation of their findings, as under these conditions 
the enhancing effect of released ADP and subsequent P2Y12 receptor 
signalling becomes insignificant (compare chapter 6.1.1 and Fig. 6). 
In support of our observations, Soulet et al. (2004) demonstrated in chinese 
hamster ovary cells stably expressing the P2Y12 receptor, although an 
artificially created system, that ERK2 is activated by 2-MeS-ADP via P2Y12 
receptor signalling in a PI 3-K-dependent manner. 
As integrin αIIbβ3, that upon fibrinogen binding negatively affects ERK2 
activation, is likewise activated by P2Y12 receptor-mediated PI 3-K activation, a 
key role for PI 3-K for the regulation of ERK2 activity can be proposed. 
 
As mentioned in the Introduction section, ERK2 becomes activated by the 
highly substrate- and dual-specific ERK upstream kinases MEK1 and 2. 
In this study, the two pharmacologically unrelated MEK1/2 inhibitors U0126 and 
PD98059 were applied. As expected and previously shown, both inhibitors 
prevent thrombin-induced ERK2 activation in concentration-dependent fashions 
(Fig. 20, Börsch-Haubold et al. 1996, Rosado et al. 2001). Whereas U0126 at 
3 µM almost completely prevents ERK2 activation in response to 0.1 U/ml 
thrombin, a concentration of 10 µM of PD98059 is required to receive a 
comparable effect. 
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On the level of the cooperation of G protein-mediated signalling the following 
simplified scheme summarizes the basic mechanisms involved in platelet ERK2 
activation and regulation in response to the primary platelet agonists thrombin 
and collagen: 
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In brief, thrombin initiates ERK2 activation as well as the release of TXA2 and 
ADP via Gq signalling, which in turn is synergized by TXA2. Released ADP 
accomplishes ERK2 activation by PY212 receptor mediated Gi signalling. 
Collagen-provoked ERK2 activation also requires Gq- and Gi-coupling which 
are achieved by released TXA2 and ADP, respectively. PKC and/or calcium 
trigger ERK2 activation as well as the release of the platelet-derived secondary 
mediators TXA2 and ADP in response to both thrombin and collagen. 
Gi-coupling, that alone is insufficient to evoke ERK2 activation, can be 
mimicked by non-platelet-derived epinephrine. Gi-amplified ERK2 activation is 
mediated by PI 3-K and MEK1/2. PI 3-K activation by Gi-signalling is also a 
prerequisite for integrin αIIbβ3 outside-in signalling that down-regulates ERK2 
activity, implying a key role for PI 3-K in the regulation of ERK2 activity. 
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6.5 Protein kinase B (Akt) is not a downstream target of ERK2 
The serin/threonine kinase Akt, also designated protein kinase B (PKB), 
becomes activated in platelets stimulated with thrombin, the TXA2-mimetic 
U46619, and collagen (Kroner et al. 2000, Cho et al. 2002, Barry et al. 2002).  
Human platelets contain two isoforms of Akt, which are Akt1 (PKBα) and Akt2 
(PKBβ) (Kroner et al. 2000). For full Akt activity, besides its translocation to the 
cell membrane, the independent phosphorylation of both Thr-308 and Ser-473 
is required. Akt activation is prevented by PI 3-K inhibitors (Burgering et al. 
1995) and in thrombin-stimulated platelets dual-phosphorylation of Akt strongly 
relies on P2Y12 receptor signalling (Kim et al. 2004). Whereas the 
phosphatidylinositol-dependent kinase 1 (PDK1) has been demonstrated to 
phosphorylate Thr-308 (Stokoe et al. 1997), the kinase that phosphorylates 
Ser-473 is not yet identified. Nevertheless, due to its function it has been 
designated PDK2. 
As thrombin-induced Akt Ser-473 phosphorylation lags behind ERK2 activation 
(Figs. 21 and 22, Kim et al. 2004) an involvement of ERK2 in Akt Ser-473 has 
been investigated. As mentioned above and shown in Fig. 19, the PI 3-K 
inhibitors LY294002 and wortmannin both effectively decreases and abrogates 
ERK2 activation as well as, and even more potently, Akt Ser-473 
phosphorylation (Fig. 25). 
On the other hand, the MEK1/2 inhibitors U0126 and PD98059, both at a 
concentration of 10 µM that entirely inhibit thrombin-induced ERK2 activation 
(Fig. 20), have no effect on Akt Ser-473 phosphorylation (Fig. 23). 
These findings indicate that ERK2 and Akt are activated by different signalling 
pathways diverging downstream of P2Y12 receptor-mediated PI 3-K activation. 
Interestingly, whereas thrombin-induced Akt phosphorylation at Ser-473 is 
already inhibited by LY294002 and wortmannin when applied at 10 and 0.1 µM, 
respectively, higher inhibitor-concentrations are obviously required for ERK2 
inhibition (Figs. 22 and 19). As such, different PI 3-K isoforms might be involved 
in P2Y12 receptor signalling. Platelets express three of the four cell surface 
receptor-activated “class I” isoforms, namely PI 3-Kα, PI 3-Kβ, and PI 3-Kγ 
(Jackson et al. 2004). Akt phosphorylation in response to thrombin, U46619, 
and ADP has been reported to be impaired in PI 3-Kγ-deficient mouse platelets 
 61 
(Hirsch et al. 2001, Li et al. 2003). On the other hand, the P2Y12 receptor-
dependent and PI 3K-mediated activation of the small guanosine tri-
phosphatase Rap1B is not affected in mouse platelets lacking PI 3-Kγ, 
indicating that a different isoforms of PI 3-K is involved (Woulfe et al. 2002, 
Lova et al. 2002, Lova et al. 2003). 
 
 
6.6 ERK2 is neither involved in α- and dense granule secretion nor 
in integrin αIIbβ3 activation or platelet aggregation 
The relevance of ERK2 activation in non-nucleated platelets is not yet clear. 
Whether ERK2 participates in platelet activation and aggregation is 
controversially discussed. 
Therefore, the consequence of the preclusion of ERK2 activation with MEK1/2 
inhibitors on primary platelet responses such as secretion of α- and dense 
granules as well as integrin αIIbβ3 and final platelet aggregation has been 
investigated. Pretreatment with U0126 or PD98059, both at 10 µM which 
completely blocks ERK2 activation (Fig. 20), slightly but significantly attenuates 
dense granule secretion but does neither affect α-granule secretion, nor integrin 
αIIbβ3 activation, or platelet aggregation (compare “Results” section, chapters 
5.6.1 and 5.6.2). In addition, all the examined events associated with platelet 
activation and aggregation are in most part completed prior to the onset of 
ERK2 activation. Finally, low concentrations of the examined agonists such as 
0.05 U/ml thrombin, 1 µM U46619, or 1 µg/ml collagen, which do not or only 
marginally induce ERK2 activation, were sufficient to cause aggregation in most 
platelet preparations. These findings support previous reports suggesting that 
ERK2 activity is dissociated from primary platelet activation and aggregation 
(Börsch-Haubold et al. 1996, McNicol et al. 2003). 
In contrast, it has been reported by Börsch-Haubold et al. (1998) that inhibitors 
of the MAP/ERK-activating kinases MEK1/2 affect platelet aggregation induced 
by low concentrations of collagen. Similar observation were made by Li et al. 
(2001) in platelets stimulated with low concentrations of thrombin and the 
authors further even proposed a role for ERK2 in integrin αIIbβ3 activation. 
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However, extensive studies, in particular from Phillip Cohen’s group, 
determining the specificity of various kinase inhibitors suggest that most, if not 
all inhibitors available affect one or more enzymes besides their specific or 
actual targets (Davies et al. 2000, Bain et al. 2003). Hence, data obtained 
applying such inhibitors should be interpreted with caution and the use of 
various, structurally and mechanistically unrelated inhibitors is strongly 
recommended. 
Along this line, U0126, besides its ability to inhibit ERK2 activation, seems to 
affect a protein kinase C-dependent but ERK2-unrelated pathway (McNicol et 
al. 2003), and therefore may interfere with ADP secretion induced via Gq-
coupled receptors. This might explain the observed attenuation of thrombin-
induced dense granule secretion by U0126 as well as the by Li et al. (2001) 
reported inhibition of thrombin-induced platelet aggregation and proposed 
engagement of ERK2 in integrin αIIbβ3 activation. 
PD98059 has been demonstrated to directly inhibit cyclooxygenase-1 and -2 
(Börsch-Haubold et al. 1998) and, as such, interferes with TXA2 synthesis that 
is essentially required for platelet activation and aggregation in response to 
moderate concentrations of collagen (for review see Nieswandt et al. 2003) and 
synergizes with thrombin in ERK2 activation (Fig. 10). 
Although P2Y12 receptor signalling is involved in platelet activation and 
aggregation in response to thrombin, collagen, and TXA2, the presented data 
further indicate that ERK2 activation is dissociated from these events. 
Whereas p38 MAPK isoforms have been implicated in platelet activation and 
aggregation in response to thrombin, collagen, TXA2 mimetics, and calcium 
ionophores (Kramer et al. 1995, Saklatvala et al. 1996), still less in known about 
the role(s) and substrate(s) of ERK1 and ERK2. 
The ERK pathway has recently been demonstrated the be involved in the 
activation of store-mediated calcium entry and, therefore, platelet calcium 
homeostasis (Rosado et al. 2001, 2002), representing the first functional 
implication for ERK in human platelets. 
It has further been reported that ERK2 translocates into the cytoskeleton of 
activated platelets and been suggested that ERK2 might play a role in 
cytoskeletal rearrangement or that the cytoskeleton serves as a frame to align 
ERK2 with its substrates (McNicol et al. 2001). Recently, more detailed studies 
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by Pawlowski et al. (2002) demonstrated that only small amounts of ERK2 
(about 14%), and mostly in a mono-phosphorylated and therefore inactive form, 
translocates to the cytoskeleton whereas the dual-phosphorylated active form 
was found in the cytosolic fraction. 
 
Taken together, the present work clearly demonstrates that ERK2 is a target 
molecule markedly affected by the P2Y12 ADP receptor-induced signalling 
pathway. 
In addition, it has been elucidated that the quantitatively fine-tuned cooperation 
of primary signalling through Gq, which evokes ADP secretion, as well as 
subsequent coupling via Gi by the P2Y12 ADP receptor are required for ERK2 
activation in human platelets. 
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8 SUMMARY 
 
 
The study elucidates the signalling pathways involved in the activation and 
regulation of the extracellular signal-regulated kinase 2 (ERK2) in human 
platelets. 
ERK2 activation in response to primary platelet agonists such as thrombin and 
collagen strongly, albeit not exclusively, relies on the release and subsequent 
action of the platelet-derived secondary mediators thromboxane A2 (TXA2) and 
adenosine 5'-diphosphate (ADP). The cooperation of Gq-signalling, induced by 
thrombin or TXA2, and Gi-signalling by the P2Y12 ADP receptor is required. 
Both Gq and Gi are indispensable for ERK2 activation. The intensity of one 
pathway limits the effect of the other. The quality and strength of the Gq signal 
determines the release of ADP and, in turn, the amplifying potency of P2Y12 
receptor-mediated Gi signalling. Gi signalling alone is not sufficient to evoke 
ERK2 activation. On the other hand, subthreshold Gq signalling input is 
amplified by Gi signalling when induced by exogenously added 2-MeS-ADP or 
epinephrine. 
As such, platelet ERK2 activation is achieved by a fine-tuned and well-balanced 
synergism of Gq and Gi. 
Gq- and Gi-induced pathways are likewise required for integrin αIIbβ3 activation. 
In platelets, fibrinogen binding and subsequent integrin αIIbβ3 outside-in 
signalling down-regulates ERK2 activity. Phosphoinositide 3-kinase (PI 3-K) 
mediates Gi-induced activation of ERK2 as well as of integrin αIIbβ3, implying a 
regulatory key role of PI 3-K in ERK2 activity. 
ERK2 net activity is determined by Gq/Gi-induced ERK2 phosphorylation and 
integrin αIIbβ3-dependent dephosphorylation. 
Platelet responses such as the release of α- and dense granules, activation of 
integrin αIIbβ3, as well as platelet aggregation are dissociated from ERK2 
activation. 
In summary, the present work demonstrates that platelet ERK2 activation is 
precisely regulated by cooperation of Gq- and Gi-mediated signalling pathways 
but is not implicated in granules secretion and platelet aggregation. 
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